

Pediatric Gastroenterology Hepatology & Nutrition

*M.D. and Ph.D.
Fellowship Training Program*



Benjamin L. Shneider, M.D.

Section Head

Carol A. Redel, M.D.

Fellowship Director

Douglas G. Burrin, Ph.D.

Director of Research Training

Kristen Van Buren, M.D.

Associate Fellowship Director

Robert J. Shulman, M.D.

Associate Director of Research Training



**Baylor
College of
Medicine**

TABLE OF CONTENTS

| | |
|---|---------|
| Message from the Section Head and Physician-in-Chief..... | 2 |
| Background of the Program | 3 |
| Clinical & Research Faculty | 4 |
| M.D. RESEARCH TRAINING / COURSEWORK..... | 5 |
| M.D. CLINICAL TRAINING..... | 6 |
| M.D. RESEARCH TRAINING / BASIC SCIENCE VS. CLINICAL..... | 7 |
| M.D. and Ph.D. Research Training Overview | 8-9 |
| Conference Schedule / Visiting Faculty / Benefits | 10 |
| Scientific Meetings / Job Placement | 11 |
| Current Positions of Former Trainees | 12 - 13 |
| The Educational Environment | 14 - 17 |

- **Baylor College of Medicine**
- **Baylor Clinical Scientist Training Program**
- **Texas Medical Center Digestive Disease Center**
- **Department of Pediatrics**
- **Fellow’s Day**
- **Children’s Nutrition Research Center**
- **Texas Children’s Hospital**
- **Gastrointestinal Procedures Suite**
- **Motility Center**
- **Camp SIA**
- **Camp K’aana**
- **Gastroenterology Nursing Staff**
- **Inflammatory Bowel Disease Center**
- **Peds-Cori Research Center**
- **Liver Center**
- **Center for Childhood Obesity**
- **Texas Children’s Hospital Microbiome Center**
- **Center for Pediatric Abdominal Pain Research**
- **The Houston Center for Quality of Care and Utilization Studies**
- **The Inter-Departmental Translational Biology & Molecular Medicine Graduate Program**

| | |
|----------------------------------|---------|
| The Texas Medical Center | 18 |
| The City of Houston | 19 |
| Faculty Research Interests | 20 |
| Faculty Table of Contents..... | 21 - 24 |
| Faculty Descriptions..... | 25- 58 |
| Eligibility Criteria..... | 59- 64 |



Message from the Head of Section

I am delighted that you are interested in the training programs here at Texas Children’s Hospital and the Baylor College of Medicine. Our fellowship offers a tremendous opportunity for both breadth and depth of investigation in clinical, translational and basic investigation. Teaching and investigation are key components of our mission statement, “to strive for outstanding and compassionate patient care through evidence-based and expert practice achieved through research and education.” There has been exciting growth in the programs at Texas Children’s Hospital and in our Section of Pediatric Gastroenterology, Hepatology and Nutrition. Our basic research laboratories have been completely renovated and re-equipped with state-of-the-art molecular instrumentation. Clinical research has been reinvigorated in the section with the development of a clinical research coordinator team and we now conduct over 130 IRB approved clinical research protocols. Our teams are actively involved in a number of NIH-funded clinical consortia. We will continue to push the boundaries of our knowledge and our research and clinical practice – we hope you will consider joining us.

Benjamin L. Shneider, MD
George Peterkin Endowed Chair in Pediatrics
Professor of Pediatrics and Head of Section,
Pediatric Gastroenterology, Hepatology and Nutrition
Baylor College of Medicine
Chief of Service, Pediatric Gastroenterology, Hepatology



Message from the Department Chair


Baylor College of Medicine and Texas Children’s Hospital have a long and illustrious history of excellence in patient care, research, education and service in the areas of pediatric gastroenterology, hepatology and nutrition. Our commitment is to have comprehensive programs in these areas second to none worldwide, and we feel we are well on the way to achieving that. Houston, Texas is the most diverse big city in America. It provides an amazingly rich milieu in which to live and train. Our Department of Pediatrics is the largest in North America, with more than 1100 faculty members. I often say that we are the largest aggregation of pediatric subspecialists on the planet! With more than \$100 million annually in extramural research funding, the Department supports an impressive array of investigators and research activities, driving innovation to transform pediatric healthcare. Texas Children’s Hospital, with more than 600 licensed beds, is the largest children’s hospital in North America, and growing. In partnership continuously since 1954, Baylor and Texas Children’s will always expand your horizons and never limit your possibilities. We will dedicate ourselves to supporting you in every conceivable way. We welcome your interest in our training programs.

Mark W. Kline, M.D.
Physician-in-Chief
Texas Children’s Hospital
J.S. Abercrombie Professor and Chairman
Ralph D. Feigin Chair

**Section of Pediatric Gastroenterology, Hepatology, and Nutrition
Baylor College of Medicine, Texas Children’s Hospital
6621 Fannin Steet, CC1010.00, Houston, TX 77030**

Tel: 832-822-3131

<https://www.bcm.edu/departments/pediatrics/sections-divisions-centers/gastroenterology-hepatology-nutrition>



BACKGROUND

The Nutrition and Gastroenterology Fellowship Training Program was established in 1973 by Buford L. Nichols, M.D. The Section gained national prominence under the Section Chief leadership of William J. Klish, M.D., and Mark Gilger, M.D.. Benjamin Shneider M.D. is the current Section Chief and Mark W. Kline, M.D. is the Chairman of the Department of Pediatrics.

The Department of Pediatrics is one of the largest in the U.S., over 1100 Faculty members. Baylor College of Medicine is listed 19th among all U.S. medical schools for National Institutes of Health funding, and No. 2 in the nation in federal funding for research and development in the biological sciences at universities and colleges by the National Science Foundation. The Section of Pediatric Gastroenterology, Hepatology, and Nutrition currently includes 33 faculty members and a support staff of 90. The Section was ranked number 11th nationally among digestive disorders subspecialty programs in the 2015 U.S. News and World Report Survey on the Best Children's Hospitals. The clinical training program is conducted under the auspices of Texas Children's Hospital (see p. 15) and includes 31 Faculty who perform over 27,000 annual clinic visits and 2800 procedures annually (See pg 4, 15).

Clinical training is enhanced through several Texas Children's Hospital Centers and Clinics:

| | |
|---|--|
| Center for Childhood Obesity..... | Sarah E. Barlow, M.D., M.P.H., Director |
| Gastrointestinal Endoscopy and Therapeutic Endoscopy..... | Douglas S. Fishman, M.D., Director |
| Inflammatory Bowel Disease Center..... | Richard Kellermayer, M.D., Interim Director |
| Liver Center..... | Tamir Miloh, MD, Medical Director |
| | Sundararajah Thevananther, Research Director |
| Neurogastroenterology and Motility Center..... | Bruno Chumpitazi, M.D., Director |
| PEDS-CORI Research Center..... | Douglas Fishman, M.D., Director |
| Research Training is enhanced by: | |
| NIH Institutional Training Grant (T32 DK07664) | Robert J. Shulman, M.D., Director |
| | Douglas G. Burrin, Ph.D., Associate Director |

Sub Specialty Clinics:

| | |
|---------------------------------------|---------------------------------------|
| Aerodigestive Disorders Clinic..... | Eric Chiou MD, Co-Director |
| Eosinophilic Disorders Clinic..... | Anthony Olive, M.D. Co-Director |
| GROW Clinic..... | Carol Redel, M.D., Director |
| Intestinal Rehabilitation Clinic..... | Beth Carter, M.D., Director |
| Prader-Willi Clinic..... | Ann Scheimann, M.D., Director |
| Rett Syndrome Clinic..... | Kathleen Motil, M.D., Ph.D., Director |
| Viral Hepatitis Clinic..... | Daniel H. Leung, M.D., Director |

Research training draws on faculty throughout the Texas Medical Center (p.18) and benefits from the abundant research resources of the Texas Medical Center in general and of Baylor College of Medicine in particular (p.14-17). Research opportunities range from clinical studies, including outcomes and translational research, through an array of basic science laboratories at the forefront of molecular medicine (p. 26-57).

OVERVIEW OF TRAINING

Mission Statement - To strive for outstanding and compassionate patient care through evidence-based and expert practice achieved through research and education

The goal of our Fellowship Program is to educate pediatricians to become outstanding clinicians who can also compete at the cutting edge of research in academia.

The program is designed around the guidelines developed by the North American Society for Pediatric Gastroenterology and Nutrition, and is intended to allow trainees to meet the requirements for certification by the Sub-Board for Pediatric Gastroenterology of the American Board of Pediatrics.

All entrants must have completed the equivalent of three years of ACGME accredited residency training in pediatrics.

The Fellowship Program includes clinical training and research training and is completed by all Fellows. An extended research option is offered as well. The basic training consists of 12 months of clinical training and 24 months of research training. This 36-month program includes clinical service, teaching, and research and provides the trainee with the state-of-the-art knowledge and skills required for an academic career. We recommend an additional 12 months of research training for Fellows seeking an academic career with a greater emphasis on research (either basic or clinical). A substantial salary supplementation is available for selected eligible trainees during the fourth year, as well as Baylor College of Medicine Faculty appointment at the Assistant Professor level (p. 6).

A program for Ph.D. postdoctoral GI research training is available through the NIH Institutional Training Grant (T32 DK07664). Training for up to 24 months is potentially available (see p. 8).

CLINICAL AND RESEARCH FACULTY

Clinical and Research Faculty Pediatric Gastroenterology, Hepatology and Nutrition

Chief of Section:

Benjamin L. Shneider, M.D.

Sarah E. Barlow, M.D., M.P.H.

Myriam S. Barragan, M.D.

Douglas G. Burrin, Ph.D.

Beth A. Carter, M.D.

Frank Chen, M.D., Ph.D.

Eric Chiou, M.D.

Bruno P. Chumpitazi, M.D., M.P.H.

Valentine Enemuoh, M.D.

Douglas S. Fishman, M.D.

Donna Garner, R.N., M.S.N., P.N.P.

Caroyl L. Gilbert, R.N., M.S.N, P.N.P.

G.S. Gopalakrishna, M.D.

Sanjiv Harpavat, M.D., Ph.D.

Paula M. Hertel, M.D.

Ryan Himes, M.D.

John Hollier, M.D.

Craig L. Jensen, M.D.

Lina B. Karam, M.D.

Richard E. Kellermayer, M.D., Ph.D.

Kristi D. King, M.P.H., R.D., L.D.

Seiji Kitagawa, M.D.

Daniel H. Leung, M.D.

Jennifer Maupin, M.S., R.N., C.P.N.P.

Carmen Mikhail, Ph.D.

Kathleen Motil, M.D., Ph.D.

Kenneth NG, D.O.

Anthony P. Olivé, M.D.

Yen Pham, M.D.

Priya Raj, MS, M.D.

Carol A. Redel, MNS, M.D.

Ann O. Scheimann, M.D., MBA

Vernisha Y. Shepard, M.Ed., LPC

Benjamin Shneider, M.D.

Robert J. Shulman, M.D.

Mary Elizabeth Tessier, M.D.

Sundararajah Thevananther, Ph.D.

Nicole D. Triggs, MSN, APRN, CPNP,

CPN

Kristin Whitfield Van Buren, M.D.

Bryan S. Vartabedian, M.D.

Seema Mehta Walsh, M.D.

Associated Clinical Faculty

Mary L. Brandt, M.D.....Pediatric Surgery
Darrell L. Cass, M.D.....Pediatric Surgery
Danita Czyzewski, Ph.D.....Psychiatry & Behavioral Sciences
Milton J. Finegold, M.D.....Pathology
John A. Goss, M.D.....Transplant Surgery
Paul K. Minifee, M.D.....Pediatric Surgery
Jed G. Nuchtern, M.D.....Pediatric Surgery
Oluyinka Olutoye, M.D., Ph.D.....Pediatric Surgery
Christine O'Mahony, M.D.....Transplant Surgery
David E. Wesson, M.D.....Pediatric Surgery

Associated Research Faculty

Arthur L. Beaudet, M.D.....Pediatrics, Molecular and Human Genetics
Karl-Dimiter Bissig, M.D., Ph.D.....Molecular and Cellular Biology
Robert A. Britton, Ph.D.....Molecular Virology and Microbiology
Douglas Burrin, Ph. D.....Pediatrics, Children's Nutrition Research Center
Lawrence C. Chan, M.D.....Medicine, Molecular and Cellular Biology
Margaret E. Conner, Ph.D.....Molecular Virology and Microbiology
Hashem B. El-Serag, M.D.....Medicine, Gastroenterology and Health Services
Mary K. Estes, Ph.D.....Medicine, Molecular Virology & Microbiology
Farook Jahoor, Ph.D.....Pediatrics, Children's Nutrition Research Center
Brendan Lee, M.D., Ph.D.....Pediatrics, Molecular and Human Genetics
Lenard Lichtenberger, Ph.D.....Biology and Pharmacology– *University of Texas Medical School*
David D. Moore, Ph.D.....Molecular and Cellular Biology
Marc Rhoads, M.D.....Pediatric Gastroenterology– *University of Texas Medical School*
Tor Savidge, Ph.D.....Pathology and Immunology
Noah Shroyer, Ph.D.....Medicine, Gastroenterology
Betty L. Slagle, Ph.D.....Molecular Virology and Microbiology
C. Wayne Smith, M.D.....Pediatrics, Leukocyte Biology
James Versalovic, M.D., Ph.D.....Pathology & Immunology, Genetics, Molecular Virology and Microbiology
Huda Y. Zoghbi, M.D.....Pediatrics, Molecular and Human Genetics

M.D. RESEARCH TRAINING / COURSEWORK

SCHEDULING OF RESEARCH TRAINING

Clinical and research months may be allocated in various ways. The first year of training will always have at least three research months. These months are distributed among the clinical months so that there are never more than three consecutive clinical months. A 4th research block during the first year is optional.

| | Clinical Training (months) | Research Training (months) |
|-----------------|-------------------------------|--|
| Year 1 | 8 - 4 week rotations | 4 - 4 week rotations (Includes conference and vacation) * |
| Year 2 | 0 | 12 |
| Year 3 | 4 | 8 |
| Total | 12 | 24 |
| Junior Faculty* | 0 | 12 |
| Total | 12 | 36 |

* Offered as part of the NIH T32 Training Grant (see p. 8).

COURSEWORK

There are several courses required of all trainees:

- ***Pediatric Gastroenterology, Hepatology and Nutrition:*** This didactic course is taught by several members of the Faculty. Lectures are held each Friday. Typically a full three years is required to cover all the material. An additional component of the course is a series of lectures from Dr. Burrin and other research Faculty on issues relevant to building an academic career (e.g., scientific writing, grantsmanship, etc.).
- Baylor College of Medicine and the Dept of Pediatrics offer workshops in the following ACGME required coursework: Sleep and Safety, Fellows as Teachers, Evidence-based Medicine, and Systems-based Practice, and Quality Improvement.
- ***Fundamentals of Clinical Investigation:*** A course is offered each July/August by the Department of Pediatrics to research Fellows in all divisions and generally taken by our Fellows in their second year. This is an intensive course (2 hours per day for one month), which covers biostatistics, outcomes research, clinical trials, metabolic and molecular methods, literature skills, translational research and research ethics. Our experience in training M.D. Fellows in research indicates that this course fills a variety of critical gaps in their knowledge base. An optional computer literacy course is offered in conjunction with this course.

Optional Coursework:

Molecular biology impacts all aspects of modern medicine and it is imperative that Fellows be conversant with the basic tenets of this discipline. Thus, Fellows are encouraged to update their knowledge, if necessary, by taking the eight lecture unit entitled, "Introduction to Molecular Biology," which is offered each September as part of Baylor College of Medicine core curriculum for medical students.

To enhance future research opportunities, Fellows are strongly encouraged to take the Baylor College of Medicine course entitled, "Grants and Contracts". This course typically consists of nine weekly one-hour sessions during January and February. It is an outstanding introduction to the scientific, strategic and administrative aspects of grantsmanship.

Individual research committees will evaluate each trainee's background knowledge *vis a vis* the proposed research and will recommend additional courses if necessary. Such course work typically is chosen from the offerings in the Baylor College of Medicine Graduate Program.

M.D. CLINICAL TRAINING

Dr. Carol Redel is the Fellowship Director responsible for clinical training and program administration. The other members of the clinical Faculty are listed on page 4.

Inpatient: All Fellows receive 12 months of inpatient training in clinical Gastroenterology, Hepatology and Nutrition at Texas Children's Hospital. The inpatient service is divided into of three "teams," each consists of a Fellow and an attending physician. Two teams alternate call days with the on-call team being responsible for consults overnight. The third team handles daytime consults at Texas Children's Hospital.

- Consults are done on an average of four to six new patients each day. In addition to consults, patients cared for by the Faculty also may be admitted directly to the team, in which case the Fellow and the attending physician direct the care of the patient.
- All patient care is performed by the Fellow under the supervision of the attending. For example, consults are done by the Fellow and then are presented to the attending physician for discussion and teaching.
- All procedures are performed by the Fellow under supervision of the attending physician.
- Monday through Thursday the Fellows are "on call" once to twice a week on alternating days. Weekend call usually occurs every ten weeks for each Fellow. Fellows take night call and weekend call from home. There is a second fellow on call Saturday 5pm– Sunday 7am to allow the primary weekend fellow a rest period from consults in patient issues, an parent phone calls.
- Because attending physicians rotate twice a month, the Fellow has the opportunity to work with a number of different Faculty and, as a result, is exposed to a variety of clinical perspectives.

Outpatient: Through all years of the Fellowship, the trainee attends Gastroenterology, Hepatology and Nutrition outpatient clinics.

- Second and third year fellows have responsibility for continuity patients through a weekly 1/2 day Fellows' Clinic. Fellows' clinic is staffed by selected teaching faculty. During Fellows' Clinic there is exposure to initial evaluation and diagnostics, clinical management, and patient follow up for the duration of fellowship training. Responsibility for all patient/family communication belongs to the continuity fellow, with coverage arranged among fellows during times the fellow is unavailable
- All Fellows rotate through the Nutrition related Clinics during their first year.
- Optional outpatient rotations include the General Gastroenterology Clinics, Eating Disorders Clinic, Feeding Disorders Clinic, Prader-Willi Clinic, Grow Clinic, and Intestinal Rehabilitation Clinic, Eosinophilic Disorder Clinic.

Skills: Expertise that the trainee will acquire includes:

- Diagnostic and management skills in a wide array of gastrointestinal, hepatic, pancreatic and nutritional disorders.
- State-of-the-art training in gastrointestinal procedures, including diagnostic upper and lower endoscopy, therapeutic endoscopy (e.g., stricture dilation, variceal band ligation), intestinal motility, and capsule endoscopy.

Other Activities: Fellows have the opportunity to participate in the activities of a number of other clinical services and teams run by the Section of Pediatric Gastroenterology, Hepatology and Nutrition. These services are provided by the following groups:

- The Liver Transplant Program is fully integrated into the care of pre/post liver transplant patients within the Liver Center. In order to provide optimal care for these complex patients, a "team approach" is practiced using our surgeons, transplant surgeons, coordinators, hepatologists, and other care givers.
- The Grow Clinic provides multidisciplinary evaluation and treatment of children with psychological and/or physiological feeding problems. The Grow Clinic evaluates and treats infants and children with failure to thrive or failure to eat.
- The Prader-Willi Clinic provides comprehensive treatment of this genetic disorder.
- The Inflammatory Bowel Disease Clinic provides consultation for the complex medical and psychosocial aspects of this disorder.
- The Motility Clinic provides evaluation, therapy, and research of childhood functional and motility gastrointestinal disorders.

M.D. RESEARCH TRAINING / BASIC SCIENCE VS. CLINICAL

CHOICE OF BASIC SCIENCE OR CLINICAL RESEARCH PROJECT

M.D. Fellows may choose either a basic science or clinical research project. Because few Fellows have had basic science training, it is expected that one or more of their research rotations in the 1st year will be in a basic science laboratory (see overview p. 8). Our experience is that many Fellows decide to pursue basic science after their research rotations. Ultimately, it is the Fellow's choice whether to pursue a basic science or clinical project.

BASIC SCIENCE PROJECT

All basic science mentors have extensive experience working with M.D. Fellows. Even Fellows who have had no exposure to basic science, after a short time, find themselves comfortable in this environment because of the mentor's ability to successfully integrate M.D. Fellows into their laboratory. As noted on page 5, Fellows also are encouraged to take the eight lecture unit entitled, "Introduction to Molecular Biology," which is offered each September as part of Baylor College of Medicine core curriculum for medical students to expedite their education if needed.

CLINICAL RESEARCH PROJECT

Fellows choosing a clinical project will work with their mentor to develop a protocol for approval by the Baylor College of Medicine Institutional Review Board. Because the size of our patient population is unsurpassed, opportunities for clinical research abound.

As part of this program, Fellows who choose a clinical research project and are approved for support by our NIH T32 Training Grant enter the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in their 2nd year of Fellowship (1st year on the NIH T32 Training Grant). The CSTP offers an M.S. degree in clinical investigation through the BCM Graduate School of Biomedical Sciences. Three core courses in the CSTP are: a) Fundamentals of Clinical Investigation - modules include Interpreting the Clinical Research Literature, Ethics in Clinical Research, Clinical Trial Design and Analysis, Biostatistics; b) Clinical Investigation for the Career Scientist - modules include Grant Writing, Translational Research, Leadership training, Health Services Research, and Clinical Decision Analysis; and c) Seminar - where Fellows present their research to the class, starting with the hypotheses and specific aims, and advancing to the methods and analyses. They receive constructive criticism from the course directors as well as their peers. During this period Fellows write a K23 research grant proposal.

APPOINTMENT AS JUNIOR FACULTY

M.D. Fellows who are appointed to the NIH T32 Training Grant (see p. 8) have the potential to extend their research training an additional 12 months. Fellows that choose this option and who are approved by the leadership of the T32 and section receive a Faculty appointment at the Assistant Professor level in addition to a substantial salary increase offered by the Department of Pediatrics. This offer may be extended to Fellows who submit an application for external research funding prior to the start of the fourth year of training. This unique opportunity not only provides financial stability, but also the ability to significantly advance the Fellow's academic career.



M.D. AND PH.D. RESEARCH TRAINING OVERVIEW

RESEARCH TRAINING

Dr. Douglas Burrin oversees the research training of the Fellows. The Section has maintained a NIH T32 Institutional Training Grant since 1991, administered by Dr. Robert Shulman, Principal Investigator. This grant provides funds for selected M.D. and Ph.D. Fellows with long term interests in research. The research training program is designed to accommodate a wide range of research experience and the individual interests of each trainee.

For M.D. Fellows: during year one, 3 one-month blocks of training are dedicated to research rotations. This gives the Fellow firsthand experience and provides the basis of choosing a mentor and an area of research interest. Throughout these rotations, the Fellow continues participation in the Gastroenterology, Hepatology and Nutrition outpatient clinics. This ensures that the Fellow is never totally removed from clinical activities.

As noted previously, the training program for M.D. Fellows includes a minimum of 24 months of research training and is designed to fulfill the research requirements that must be met by a Fellow before he/she is eligible to take the sub-board examination in pediatric gastroenterology. The official position of the sub-board on the research requirements can be found on pages 60-64. These requirements emphasize the importance of research training in the education of an academic pediatric gastroenterologist.

For Ph.D. Fellows: the expectation is that 24 months of research support will be provided. During this time, work also is geared toward obtaining future research support for the Fellow (e.g., NIH F32 grants) and preparing them for an academic career and the transition to a full-time Faculty position.

THE RESEARCH PROJECT

Each M.D. and Ph.D. trainee pursues a research project under the direction of a mentor selected from the list of potential mentors (p. 20). Mentors are chosen on the basis of solid research, a good track record in training new investigators, and a strong desire to see our Fellows have a successful research career. To facilitate the choice of mentor, M.D. Fellows spend their first three research months rotating between candidate mentors. Ph.D. Fellows directly select a research mentor from among Training Grant mentors (p. 20). After selecting a research mentor and identifying a research project, each trainee forms an individual research committee including the mentor and three (or more) additional members. Dr. Burrin serves as chairman of the research committee.

Using research committee members as consultants, the Fellow writes a research proposal, which will be the foundation for studies to be completed during the research years. This proposal is reviewed by the research committee and orally defended before this committee. M.D. and Ph.D. Trainees present an oral progress report to their committee at least twice per year. They also are expected to give a presentation at the Pediatric GI Research Workshop once per year. Additional meetings of the research committee are called as needed.

NIH T32 TRAINING GRANT

Only selected M.D. Fellows receive support from this prestigious training award and it is viewed as an important commitment toward a research career in academic medicine. M.D. Fellows apply for Training Grant support in the Spring of their first year of Fellowship. The Training Grant provides research support for up to 36 months for M.D. Fellows.

All Ph.D. Fellows are supported by the NIH T32 Training Grant. Ph.D. candidates interested in the program can submit an application any time throughout the year provided that a slot is available. Applicants selected into the program are usually supported for 24 months.

M.D. AND Ph.D. - SIDE BY SIDE TRAINING

A unique and valuable facet of our program is that M.D. and Ph.D. Fellows interact not only in the laboratory, but in joint training activities (see p. 9). By bringing their specific knowledge base to the table, the education of both clinical and basic Fellows is enhanced. Further, when M.D. and Ph.D. Fellows (and their mentors) come together, it stimulates teamwork and the development of translational research, which is a cornerstone of modern medicine.

M.D and Ph.D. RESEARCH TRAINING OVERVIEW

PEDIATRIC GI WORKSHOP

This biweekly meeting is held over the noon hour and hosts presentations by Faculty and Fellows. The meeting is designed for Fellows and Faculty to share their research findings and foster collaboration among researchers with an interest in pediatric gastroenterology, hepatology and nutrition within Baylor College of Medicine and other outside institutions. All Fellows are required to present their research progress in this workshop each year. Twice per year, the workshop also hosts a "Visiting Young Investigator" considered as an up and coming person in pediatric gastroenterology to present their research and meet informally with our Fellows and Junior Faculty to discuss how to launch an academic career.

PEDIATRIC GI JOURNAL CLUB

This is a monthly gathering of Fellows and Faculty involved in our research training program. The meeting is designed to have Fellows select a clinical and basic science journal article that highlights a new research concept or advance with relevance to pediatric gastroenterology, hepatology and nutrition. The journal club is organized by the 2nd year Fellows and all trainees are required to present one clinical and one basic science article per year. Each Fellow leads an informal discussion of the design, outcomes and significance of the paper. The meetings are held in the evenings, hosted in the homes of our Faculty mentors, and includes dinner. These meetings are a vital social gathering for interaction among Fellows and Faculty to discuss their research and get acquainted personally. New collaborations and ideas often emerge from these meetings.

PEDIATRIC GI SCIENTIFIC SOCIAL

This is a quarterly meeting among Faculty and Fellows involved in the NIH Training Grant. The meeting is held in the evening and is designed to be a more intimate and informal gathering that includes dinner at a site in the Texas Medical Center. The program invites two mentors and one trainee from the Training Grant to give a brief, informal overview of their research intended to foster interaction, questions, and feedback among the attendees. The goal of this program is to give Fellows an opportunity to "think on their feet" and respond to feedback from Faculty mentors on their research. It also is another effective forum that often leads to research collaborations among Faculty mentors.

DIGESTIVE DISEASE CENTER GI FORUM

This is a weekly seminar series hosted by the Texas Medical Center Digestive Disease Center (DDC) (see p. 14) where local Faculty and invited guests from around the U.S. present their research in the areas of gastroenterology and hepatology. The DDC is an integral component of the GI and liver research community in the Texas Medical Center and brings together Faculty from Baylor College of Medicine, University of Texas Health Science Center, M.D. Andersen Cancer Center, Rice University, University of Houston, and Texas A&M Institute of Biosciences and Technology. The DDC also hosts the Annual Frontiers in Digestive Disease on the Texas Medical Center campus, which is a one day thematic symposium that features oral presentations from invited speakers, local Faculty, and trainees along with a poster sessions. It is yet another forum for our trainees to interact, network and socialize with Faculty and other members of the GI research community in Houston.

CAREER DEVELOPMENT WORKSHOPS

These are informal lectures given by training grant Faculty on vital skills and knowledge needed for successful Fellowship and Junior Faculty research career. Topics include how to write a manuscript, how to get published in peer-reviewed journals, how to apply for NIH grant funding, and how to prepare oral presentations and posters for scientific meetings. Similar presentations on these and other career development topics are also given during the Baylor College of Medicine Department of Pediatrics Fellows Day held annually in the Spring.

CONFERENCES / VISTING FACULTY / BENEFITS

CONFERENCE SCHEDULE

Conferences are an important part of any Fellowship training program. The Section of Gastroenterology, Hepatology and Nutrition holds conferences on a regular basis in addition to those held by the Department of Pediatrics. The following table shows the current calendar. Asterisks (*) denote required conferences for M.D. Fellows. Daggers (†) indicate required conferences for Ph.D. Fellows. Other conferences are optional, depending on the Fellow's interests and time

| Day | Time | Conference |
|--|-------------------|--|
| Monday | 12:00pm - 1:00pm | * † GI Research Workshop (first and third Monday) |
| | 12:00pm - 1:00pm | *GI Pathology Conference (fourth Monday) |
| | 12:00pm - 1:00pm | *Liver Pathology Conference (second Monday) |
| | 1:00pm - 2:00pm | Hepatology Team Conference |
| Tuesday | 12:00pm - 12:45pm | *Faculty and Fellows Meeting (monthly, second Tuesday) |
| | 12:45pm - 1:45pm | *Pedi GI Grand Rounds (monthly, second Tuesday) |
| | 1:00pm - 2:00pm | *GI Case Conference (weekly/except second Tuesday of month) |
| | 6:00pm - 7:30pm | * † Journal Club (first Tuesday of month, except Jan, and July) |
| Wednesday | 1:00pm - 2:00pm | Liver Transplant MRB Conference (weekly) |
| Thursday | 8:30am - 9:30am | Children's Nutrition Research Center Conference (weekly) |
| | 12:00pm - 1:00pm | IBD Conference (Monthly, 1st and 4th weeks) |
| | 12:00pm - 1:00pm | Team E Conference (Monthly, 2nd week) |
| | 12:00pm - 1:00pm | Clinical Research Conference (Monthly, 3rd week) |
| *IBD Conference, Team E Conference, and Clinical Research Conference are rotating conferences | | |
| Friday | 8:30am - 9:30am | Pediatric Grand Rounds (weekly) |
| | 12:00pm - 1:00pm | *Pediatric Gastroenterology, Hepatology and Nutrition Fellow Core Curriculum |

constraints.

VISITING FACULTY PROGRAMS

Because of its size of and the amount of activity in the Texas Medical Center, we are afforded numerous opportunities to interact with visiting clinicians and researchers. In addition, the Section of Gastroenterology, Hepatology and Nutrition has its own invited speaker program, known as the Visiting Young Investigator series which is funded by our NIH T32 Training Grant. In this series, young pediatric gastroenterologists from around the country with established research credentials are brought in as role models for our senior Fellows and Junior Faculty. Each investigator gives a formal research seminar at the GI Research Workshop (see above) and has informal discussions (including career advice) with the Fellows and Junior Faculty.

VACATION AND BENEFITS

All Residents and Fellows are provided 44 paid days off per academic year (July 1 – June 30). This time off is non-vested (meaning the house staff physician is not paid for it if he or she leaves before having utilized), does not accrue, and does not roll over from one academic year to the next. These 44 days include:

***21** vacation days

***14** sick days (to be used only for personal illness)

***9** paid time off (PTO) days

This includes personal days, holiday, and educational leave (standard leave).

Jury Duty: Paid leave will be provided for jury duty as required by law.

SCIENTIFIC MEETINGS/ JOB PLACEMENT

NATIONAL SCIENTIFIC MEETING ATTENDANCE OPPORTUNITIES

Each M.D. and Ph.D. Fellow is provided with travel funds to attend one national conference per year. Additional conference travel funds may be available if the Fellow is presenting a paper or a poster, but permission must be sought individually from the Chief of the Section. Examples of typical annual conferences attended by Fellows and Faculty are:

- North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (held in November)
- Digestive Disease Week - A combined meeting of American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society for Gastrointestinal Endoscopy, Society for Surgery of the Alimentary Tract (held in May)
- American Association for the Study of Liver Diseases (held October/November)
- Pediatric Academic Societies' Annual Meeting - Sponsored by American Pediatric Society, Society for Pediatric Research, Academic Pediatric Association, and American Academy of Pediatrics (held in May)
- Experimental Biology - Federation of American Societies for Experimental Biology is a combined meeting of the following societies: The American Physiological Society, American Society for Nutrition, American Society for Biochemistry and Molecular Biology, American Society for Pharmacology and Experimental Therapeutics, American Society for Investigative Pathology and American Association of Immunologists (held in April)

In addition to these national meetings, M.D. Fellows have the opportunity to participate in special Fellow conferences, which are organized by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN):

- First Year Fellows Conference (*sponsored by Nestle Nutrition*)
- Second Year Fellows Conference (*sponsored by Ross Labs*)
- Third Year Fellows Conference (*sponsored by Mead-Johnson*)

The sponsoring companies cover all expenses, travel, food and accommodations for these meetings. During their research time Fellows, may have the opportunity to attend small conferences in their area of research. However, total conference attendance is limited to three per year in order to protect time in the training program.

JOB PLACEMENT

Assistance in obtaining positions after Fellowship training is taken very seriously by the Faculty. In addition to opportunities that are advertised, Faculty members often are aware of unpublished openings and are dedicated to finding the best match for each Fellow. The positions of the most recent previous Fellows are listed on the following page.



CURRENT POSITIONS OF FORMER MD TRAINEES

| Name | Period Training | Current Position |
|----------------------|-----------------|---|
| Gulati, Ajay | 2004-2007 | Associate Professor of Pediatrics, University of North Carolina, Chapel Hill, NC |
| Thakkar, Kalpesh | 2004-2007 | Private Practice, Memorial Hermann Medical Group, Sugar Land, TX |
| McOmber, Mark | 2005-2008 | Assistant Professor, Phoenix Children's Hospital, Phoenix, AZ |
| Kim, Steven | 2005-2008 | Staff Physician, Kaiser Permanente, Sacramento, CA |
| Fuller, Megan | 2005-2006 | Pediatric General Surgeon, East Ky Medical Group, Pikeville, KY |
| Venkataraman, Priya | 2005-2008 | Medical Officer, FDA, Walter Reed Pediatric Gastroenterology, Silver Spring, MD |
| Kellermayer, Richard | 2006-2008 | Assistant Professor of Pediatrics, Baylor College of Medicine, Houston, TX |
| Himes, Ryan | 2006-2009 | Assistant Professor of Pediatrics, Baylor College of Medicine, Houston, TX |
| Jain, Ajay Kumar | 2006-2009 | Assistant Professor of Pediatrics, Saint Louis University, St. Louis, MO |
| Hattar, Lana | 2007-2010 | Private Practice, Wichita, KS |
| Mehta, Seema | 2007-2010 | Assistant Professor of Pediatrics, Baylor College of Medicine, Houston, TX |
| Whitfield, Lynette | 2007-2010 | Assistant Professor of Pediatrics, Baylor College of Medicine, Houston, TX |
| Schaible, Tiffany | 2008-2011 | Assistant Professor of Pediatrics, Brenner Children's Hospital, Winston-Salem, NC |
| Cantu, Samson | 2008-2011 | Private Practice, Fort Worth, TX |
| Davidovics, Zev | 2009-2012 | Assistant Professor, University of Connecticut School of Medicine, Hartford, CT |
| Maspons, Aldo | 2009-2012 | Assistant Professor, El Paso Children's Hospital, El Paso, TX |
| Harpavat, Sanjiv | 2011-2012 | Assistant Professor of Pediatrics, Baylor College of Medicine, Houston, TX |
| Mir, Sabina | 2010-2013 | Assistant Professor of Pediatrics, University of North Carolina, Chapel Hill, NC |
| Wong, Greg | 2010-2013 | Staff Physician, Children's Hospital of Orange County, Orange, CA |
| Ng, Kenneth | 2010-2013 | Assistant Professor of Pediatrics, Baylor College of Medicine, Houston, TX |
| Chen, Leon | 2011-2014 | Private Practice, Children's Gastroenterology, MCSG, Long Beach, CA |
| Hollier, John | 2012-2015 | Assistant Professor of Pediatrics, Baylor College of Medicine, Houston, TX |
| May, Thad | 2012-2015 | Postdoctoral Research Fellow, Children's Nutrition Research Center, Houston, TX |
| Hiremath, Girish | 2013-2016 | Assistant Professor of Pediatrics, Vanderbilt University, Nashville, TN |

CURRENT POSITIONS OF FORMER Ph.D. TRAINEES

| Name | Period of Training | Current Position |
|----------------------|--------------------|--|
| Chang, Benny | 1996-1997 | Assistant Professor, Baylor College of Medicine |
| Markesich, Diane | 1998-1999 | Medical Writer & Editor, John M. Eisenberg Center for Clinical Decisions & Communication Science |
| Blutt, Sarah | 1999-2001 | Assistant Professor, Baylor College of Medicine |
| Robker, , Rebecca | 2000-2002 | Research Associate, The University of Adelaide |
| Madden, Charles | 2000-2001 | Assistant Professor, George Mason University |
| Dekaney, Christopher | 2001-2004 | Assistant Professor of Pediatrics - University of North Carolina |
| Shroyer, Noah | 2002-2003 | Associate Professor of Pediatrics, Baylor College of Medicine |
| Bressler, Jan | 2003-2005 | Assistant Professor of Pediatrics, University of Texas |
| Ochsner, Scott | 2003-2005 | Instructor, Baylor College of Medicine |
| Hutson, Anne | 2003-2005 | Medical Science Liason, Ferring Pharmaceuticals |
| Zhou, Yong | 2007-2009 | Assistant Professor, University of Texas Health Science Center |
| Antar, Alli | 2007-2009 | Instructor, Baylor College of Medicine |
| Hyser, Joseph | 2008-2010 | Assistant Professor, Baylor College of Medicine |
| Wooten-Kee, Ruth | 2008-2010 | Instructor, Baylor College of Medicine |
| Mei, Yu | 2010-2011 | Research Fellow, Harvard Medical School |
| Kathryn Pflughoeft | 2011-2012 | Postdoctoral fellow, University of Nevada School Medicine |
| Cana, Ross | 2013-2015 | Postdoctoral Research Associate at Texas Children's Hospital , Houston TX |



EDUCATIONAL ENVIRONMENT

BAYLOR COLLEGE OF MEDICINE

Baylor College of Medicine is located in the Texas Medical Center in Houston, Texas which is the world's largest medical Center. Baylor College of Medicine is dedicated to promoting health for all people through education, research and public service. The College pursues this mission by sustaining excellence in educating medical and graduate students, biomedical scientists and allied health professions, as well as advancing basic and clinical biomedical research. The College is ranked 20th overall among the nation's top medical schools for research and 11th for primary care and 9th for pediatrics in the United States. It has more than 3700 full-time, part-time, emeritus, and voluntary Faculty and conducts independent research amounting to more than \$400 million annually. The College enrolls 698 medical students in a four-year program, approximately 911 Ph.D. graduate students, more than 943 residents and Fellows in postgraduate medicine and surgery. Baylor college of medicine as more than 90 research and patient care centers. This thriving environment has fostered international recognition, especially in the Departments of Pediatrics, Molecular and Cellular Biology, Molecular Virology & Microbiology, Molecular and Human Genetics, the Howard Hughes Research Institute, and the Human Genome Center. www.bcm.edu



THE DEPARTMENT OF PEDIATRICS

Under the leadership of Dr. Mark Kline, Pediatrics is one of the pre-eminent departments in the U.S. The Department has trained more than 60% of the pediatricians in Texas and nearly 5% of all pediatricians in the United States. The Department of Pediatrics receives more than \$101 million per year in extramural grant support, the majority of which comes from NIH. In any given year, the members of the department publish more than 800 papers in the peer-reviewed medical literature. Today, the Department of Pediatrics has nearly 1100 Faculty. Some of these Faculty members provide staffing for the Pediatric Services at Ben Taub General Hospital (a public hospital that provides care to citizens of Harris County). In addition, there are also 8 research centers in specific disciplines, the most relevant to this program being the Center for Cell and Gene Therapy, the Children's Nutrition Research Center, the Obesity Center, and the Liver Center.



BAYLOR CLINICAL SCIENTIST TRAINING PROGRAM

In 1999, Baylor College of Medicine received a K-30 grant from the National Institutes of Health to establish a college-wide multidisciplinary didactic 1-5 year training program known as the Clinical Scientist Training Program. This program is committed to promoting the education and training of highly motivated Junior Faculty to become successful, independent clinical investigators and future leaders in academic medicine and biomedical research. The program offers M.S. and Ph.D. degrees in Clinical Investigation through the Graduate School of Biomedical Sciences. Both programs are designed for individuals with a significant commitment to clinical research.

M.D. trainees interested in clinical research can extend their period of training by pursuing either the M.S. or Ph.D. degree from the Clinical Scientist Training Program. The core courses for the program are entitled, Fundamentals of Clinical Investigation, Clinical Investigation for the Career Scientist, Seminar Series, and an elective (Intermediate Biostatistics at the UT School of Public Health). Fundamentals of Clinical Investigation is offered in July every year. Fulfilling the course requirements, students will write a K-23 research proposal that will be developed into a thesis and the students also will write a R01 proposal. www.bcm.edu/cstp



TEXAS MEDICAL CENTER DIGESTIVE DISEASE CENTER

Mentors and trainees associated with this training program derive significant benefit from the Texas Medical Center Digestive Disease Center (DDC). The DDC is only the 17th such NIDDK-funded center in America which promotes coordinated digestive disease activities, and the only one in the Southwest or Gulf States area. The mission of the DDC is to facilitate on-going research in digestive diseases, promote translational research between basic and clinical areas, develop new projects, nurture new investigators, and provide GI educational activities. The DDC supports three Basic Science Cores (Cellular and Molecular Morphology, Functional Genomics and Proteomics, Integrative Biology), and one Clinical Core (Study Design and Clinical Research). The Center draws together a multidisciplinary group of investigators, including basic scientists with proven tract records of success, and well coordinated clinical programs dealing with pediatric and adult GI patients.


In addition, Fellows supported on our NIH Training Grant are eligible, in their third year, to apply for pilot/feasibility funding (up to \$35,000) from the Center in order to develop research projects suitable for external funding. www.bcm.edu/gastro/DDC



EDUCATIONAL ENVIRONMENT

PEDIATRIC RESEARCH AND FELLOWS SYMPOSIUM

The Department of Pediatrics supports research training through their sponsorship of an annual research symposium where trainees have the opportunity to present their research in either oral or poster format. The symposium also includes faculty presentations on topics relevant to the development of academic physicians. www.bcm.edu/pediatrics



CHILDREN'S NUTRITION RESEARCH CENTER

The Children's Nutrition Research Center (CNRC) is the first federally funded human nutrition research center to investigate the nutritional needs of children from conception through adolescence. The 11-story Center has 50 full-time Faculty members dedicated to defining the nutrient needs of children from conception through adolescence, pregnant women, and nursing mothers. Since 1978, CNRC research has helped form the foundation of national nutrition policies and clinical nutrition practices that have improved the health of mothers and children of all ages. It is operated by Baylor College of Medicine in cooperation with Texas Children's Hospital and the Agricultural Research Service of the U.S. Department of Agriculture (USDA/ARS). The CNRC houses an Energy Metabolism and Exercise Laboratory with indirect room calorimetry, an advanced Body Composition Laboratory, a Behavioral Studies Unit and Children's Eating Laboratory. These facilities enable the Center scientists to conduct some of the world's most advanced nutritional studies, which have earned the CNRC an international reputation for research excellence. www.kidnutrition.org



GASTROINTESTINAL (GI) PROCEDURES SUITE

Texas Children's Hospital houses the 7,000-sq. ft. Gastrointestinal Procedures Suite. The GI Procedures Suite is at the cutting edge of patient care and research. More than 2,800 procedures (e.g., upper endoscopy, colonoscopy and liver biopsy) are performed each year in the Suite as well as a wide array of diagnostic tests (e.g., 24-hour esophageal pH monitoring, breath testing). The Suite is nationally known for its leadership role in sedation techniques in children and is the headquarters of the PEDS-CORI project (Pediatric Endoscopy Database System—Clinical Outcomes Research Initiative). The suite is composed of three endoscopic rooms, two non-endoscopic procedure rooms, a prep room, holding area, recovery room and endoscope disinfection room. www.bcm.edu/pediatrics



TEXAS CHILDREN'S HOSPITAL


Texas Children's Hospital (TCH) is an internationally recognized full-care pediatric hospital. It is the largest children's hospital in the United States. TCH is dedicated to providing the finest possible pediatric patient care, education and research. TCH is nationally ranked among children's hospitals by U.S. News & World Report. The hospital has garnered widespread recognition for its expertise and breakthrough developments in the treatment of cancer, diabetes, asthma, HIV, preterm babies, and cardiologic disorders. The hospital has more than 20,000 admissions and more than 200,000 clinic visits annually. The 19-story 780,000-plus-square foot Clinical Care Center houses most of Texas Children's outpatient clinics. The hospital's Feigin Center is a 20-story facility dedicated entirely to pediatric research. Texas Children's Hospital is Houston's only freestanding children's hospital and is the primary teaching hospital of Baylor College of Medicine. The hospital's award-winning medical staff consists of more than 1,580 board-certified, primary-care physicians, pediatric subspecialists, pediatric surgical subspecialists, and dentists. In addition, TCH offers a dedicated and highly skilled nursing staff, health care professionals and support of more than 6,000.

Also located adjacent to the Clinical Care Center is the TCH Pavilion for Women which provides a full continuum of family-centered care to women, mothers and their babies, beginning before conception and continuing through all the years of a woman's life. In 2018, TCH will open a new 19-floor pediatric tower with new surgical operating rooms, intensive care unit, heart center and Helipad roof.

TCH West Campus houses a 48-bed acute care hospital located 25 miles from the Texas Medical Center. It houses a pediatric emergency center, surgical suites, advanced diagnostic imaging center.

In 2017, TCH will open the Woodlands Campus with a 560,000-square-foot, state-of-the-art facility with 25 emergency center rooms, 72 outpatient rooms, 12 radiology rooms, four operating rooms, 28 critical care beds and 32 acute care beds with plans to add up to 200 additional beds

www.texaschildrens.org




EDUCATIONAL ENVIRONMENT

THE MOTILITY CENTER

The Neurogastroenterology and Motility Center at Texas Children's Hospital's goal is to provide world-class evaluation, therapy, and research in childhood functional and motility gastrointestinal disorders. Since 2008, a full motility laboratory including state-of-the art high resolution manometry, esophageal impedance, and breath testing has been available for diagnostic evaluations. All GI Fellows will have exposure to patients seen within the Center, and are welcome to attend Center outpatient clinics, observe/perform manometry procedures, or choose a research project relating to functional or motility disorders.

www.bcm.edu/pediatrics



THE HOUSTON CENTER FOR QUALITY OF CARE AND UTILIZATION STUDIES (HCQCUS)

The HCQCUS subsumes both the Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development (HSR&D) Service, which is a Veteran's Administration HSR&D Center of Excellence, and the Baylor College of Medicine, Department of Medicine Section of Health Services Research. The Houston HSR&D Center of Excellence is one of the nation's 15 health services research and development centers of excellence funded by the Veteran's Administration. HCQCUS includes four Research Programs (Clinical Epidemiology and Outcomes, Health Policy and Quality Program, Health Decision-Making and Communication Program, and Health Services Delivery and Organization Program), a Design and Analysis Program, an Operations Division, and an Education Program.



CENTER FOR PEDIATRIC ABDOMINAL PAIN RESEARCH

This Center is a multidisciplinary research program focused on understanding the pathophysiology of functional abdominal pain disorders in children. Research efforts also are dedicated to the treatment and management of these conditions. The research team consists of both clinical and basic science researchers and has a multispecialty focus with the contribution of pediatric psychologists, the Texas Children's Microbiome Center, the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine, the Texas Children's Hospital Motility Center, and the Leukocyte Biology Laboratory at the Children's Nutrition Research Center. A number of national collaborations further enhance the Center's activities.

www.bcm.edu/cnrc/kidsabdominalpain/



TEXAS CHILDREN'S HOSPITAL MICROBIOME CENTER

The Texas Children's Microbiome Center is a cutting-edge laboratory housed within Texas Children's Hospital. Staffed by leading scientists in the field of metagenomic science, the Texas Children's Microbiome Center is strategically placed to partner with pediatric gastroenterology and other specialties. Clinical research coordinators are available for recording valuable information regarding the current condition of the child as well as historical medical information of importance. The Texas Children's Microbiome Center Sequencing Core is skilled in the extraction of nucleic acid from a variety of specimen types, and the TCMC provides metagenomic analysis of the gut microbiome by next-generation sequencing partnered with bioinformatics support. www.texaschildrens.org



INTER-DEPARTMENTAL TRANSLATIONAL BIOLOGY & MOLECULAR MEDICINE GRADUATE PROGRAM (TBMM)

The TBMM is a new complimentary approach to train Ph.D. trainees in translational biology and promote collaborations between clinical and basic science Faculty. This innovative program aims to develop a new breed of Ph.D. scientist with firsthand experience in translational research and leadership training to serve as a catalyst to move discoveries effectively between bench and bedside. TBMM is one of 23 programs around the country initially supported by the Howard Hughes Medical Institute Med into Grad Initiative. TBMM is also supported by an NIH T32 Training Grant from NIGMS. The program is designed to develop a cadre of Ph.D. researchers who have an understanding of medicine and pathobiology and are committed to working at the interface of the basic sciences and clinical medicine. This program facilitates interactions between basic science and clinical researchers using a unique dual mentorship. Courses in the TBMM are available to Ph.D. trainees in our Fellowship program. www.bcm.edu/tbmm

THE TEXAS MEDICAL CENTER

THE TEXAS MEDICAL CENTER


The Texas Medical Center is the world's largest medical center and it is an internationally recognized community of healing, education, and groundbreaking research. It occupies an area of more than 1000 acres, 26 miles of public and private streets and is located 5 miles south of downtown Houston. It is dedicated to medical care and research. It is Houston's largest employer, with more than 106,000 employees. The Medical Center is the home of many of the nation's best hospitals, physicians, researchers, educational institutions and health care providers.

Within the confines of the Medical Center are three medical schools (Baylor College of Medicine, The University of Texas Medical School at Houston, and Texas A&M College of Medicine) and twenty-one hospitals (including Texas Children's Hospital, St. Luke's Episcopal Hospital and its affiliate the Texas Heart Institute, Methodist Hospital, Ben Taub General Hospital, the Michael E. DeBakey Veterans' Hospital, The University of Texas at Houston affiliated Hermann Hospital, M. D. Anderson Center, Hermann Hospital Institute for Rehabilitation and Research (TIRR), and Shriner's Children Hospital.)

The Medical Center is situated in a largely residential area of Houston. Thus, abundant housing is within walking distance. Rice University's tree-lined campus is adjacent to the Medical Center, as are the recreational facilities of Hermann Park.



- 1 Alkek Bldg (BCM)
- 2 Alkek Tower
- 3 Baylor Clinic
- 4 Baylor Family Practice
- 5 Ben Taub Hospital
- 6 Ben Taub Research Center
- 7 Children's Nutrition Research Center
- 8 Cullen Building (BCM)
- 9 Dunn Tower
- 10 Texas Children's Hospital Feigin Research Center
- 11 HAM-TMC Library (Jessie Jones Bldg)
- 12 Hornberger Conference Center
- 13 Houston Medical Center
- 14 Jan and Dan Duncan Neurological Research Institute at TCH



- 15 Jewish Institute for Medical Research
- 16 John P. McGovern Commons
- 17 Lee and Joe Jamail Specialty Care Center
- 18 MD Anderson Cancer Center
- 19 Margaret Alkek Biomedical Research Building
- 20 McGovern Campus (Nabisco)
- 21 Medical Tower (Baylor Faculty)
- 22 Houston Methodist Hospital
- 23 Michael E. DeBakey Center (BCM)
- 24 Michael E. DeBakey High School
- 25 Michael E. DeBakey VA Medical Center
- 26 Neurosensory Center
- 27 O'Quinn Medical Tower
- 28 Park Plaza Hospital
- 29 Quenin Mease Community Hospital
- 30 Rice University
- 31 Scurlock Tower
- 32 Smith Research Wing
- 33 Smith Tower
- 34 Baylor St. Luke's Medical Center
- 35 TIFF (The Institute for Rehabilitation and Research)
- 36 Texas Children's Hospital
- 37 Texas Children's Hospital Clinical Care Center
- 38 Texas Children's Hospital West Tower
- 39 Texas Children's Pavilion for Women
- 40 Texas Heart Institute—Denton A. Cooley Building
- 41 University General Hospital
- 42 Baylor College of Medicine Medical Center, McNair Campus


THE CITY OF HOUSTON

FUN IN THE CITY

As the fourth largest city in the United States with more than two million inhabitants from a variety of cultures, Houston is a city of surprises. Long known for its energy industry, Houston is an international city that is a leader in the arts, education and health care. Houston is ranked #1 Metro for building wealth by Bank-rate.com. Houston ranks in the top five of America's Coolest Cities in 2014 by Forbes. It is one of only four cities in the United States with permanent companies in all performing arts: dance, symphony, opera and theater. Houston's Midtown area features an internationally known Museum District as well as a growing nightlife. Downtown is the entertainment focal point, with world-class performing arts at the Bayou Place Center for the Performing Arts, Jones Hall, the Alley Theatre, and the Wortham Center. Discovery Green is a 12-acre, downtown park featuring arts, entertainment, and children & family events all year long. The city has so many exciting attractions for everyone.

Houston is also a sports city. Outdoor sports abound due to the year-round mild climate. The beaches of Galveston are only an hour away, featuring the Historical Galveston Island Pleasure Pier, amusement park. For spectator sports fans we have the Houston Texans lead by JJ Watt, in the NRG stadium, and the Houston Rockets led by James Harden and Dwight Howard in the Toyota Center. The Houston Astros baseball team, 2005 National League Champs, is located in a downtown stadium. The Houston Dynamo, the champions of major league soccer in 2006 and 2007 have a new stadium near downtown, BBVA Compass Stadium. Houstonians now have a new way to travel to downtown for the arts and sporting events with the expanding METRO light rail.

Houston also annually hosts the Houston Livestock Show and Rodeo at the NRG Stadium, attracting millions of attendees yearly. The rodeo has been referred to as Houston's signature event. This 20 day event includes; some of the world's biggest recording artists, rodeo parade, trail rides, Bar-B-Que Contests, Carnival, and much more.



FACULTY RESEARCH INTERESTS

| | |
|-----------------------------------|---|
| Barlow, Sarah E. | Childhood Obesity and Community Intervention |
| Beaudet, Arthur* | Neuronal carnitine deficiency as a risk factor for autism |
| Bissig, Karl-Dimiter | Liver Disease and Human Disease Modeling |
| Britton, Robert A. | Basic and Translational Therapeutic Microbiology |
| Burrin, Douglas G. | Nutritional Regulation of Neonatal Gut and Liver Health and Disease |
| Carter, Beth A. | Clinical Outcomes in Parenteral Nutrition- Associated Cholestasis |
| Chan, Lawrence C. | Pathophysiology, Complications and Gene Therapy of Diabetes |
| Chiou, Eric | Disorders of Esophageal Motility |
| Chumpitazi, Bruno P. | Clinical Diagnosis, Treatment, & Outcomes of Pediatric Functional and Motility GI |
| Conner, Margaret E. | Pathogenesis of Intestinal Viral Infections |
| El-Serag, Hashem B. | Clinical Epidemiology and Outcomes of GI and Liver Disorders |
| Estes, Mary K. | Gastrointestinal Virus-Cell Interactions, Pathogenesis and Immunity |
| Finegold, Milton | Cholestatic and Neoplastic Liver Diseases in Children |
| Fishman, Douglas | Advances in Therapeutic Endoscopy and Pancreaticobiliary Disease |
| Harpavat, Sanjiv | Developmental Etiology and Clinical Studies of Biliary Atresia |
| Hertel, Paula M. | Infantile Disorders of Biliary Function: Closing Current Knowledge Gaps |
| Jahoor, Farook | Intermediary Metabolism in Health and Disease |
| Kellermayer, Richard | Epigenomic and Microbiomic Aspects of Inflammatory Bowel Disease |
| Lee, Brendan | Biochemical Genetics of the Urea Cycle and Nitric Oxide Synthesis |
| Leung, Daniel | Viral Hepatitis and Cystic Fibrosis Liver Disease |
| Lichtenberger, Lenard M. | Regulation of Gastric Barrier Function and Homeostasis in Health & Disease |
| Miloh, Tamir | Clinical Outcomes in Pediatric Liver Transplantation |
| Moore, David D. | Metabolic Regulation by Nuclear Receptors |
| Rhoads, J. Marc | Probiotic Mechanism of Action in GI Diseases |
| Savidge, Tor | Enteric Neuroimmune Microbe Interactions and Infectious Disease |
| Shneider, Benjamin L. | Basic and Translational Research in Bile Acid Homeostasis and Disease |
| Shroyer, Noah | Mechanisms that control intestinal development and homeostasis |
| Shulman, Robert J. | Functional Gastrointestinal Pain Disorders in Children |
| Slagle, Betty L. | Hepatitis B Virus Pathogenesis |
| Smith, C. Wayne | Obesity and the Inflammatory Process |
| Tessier, Mary Elizabeth | Microbiome Regulation of Enterohepatic Bile Acid Signaling |
| Thevananther, Sundararajah | Molecular Mechanisms of Liver Regeneration, NASH, and Hepatocellular Carcinoma |
| Versalovic, James | Microbiome and Probiotics |
| Zoghbi, Huda Y. | Molecular Genetic Approaches to Cell Specification and Degeneration |

* Bold font indicates a Training Grant Mentor

FACULTY

* Indicates Training Grant Mentor

Sarah E. Barlow, M.D., M.P.H. pg. 25

Associate Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Director of Obesity Center
Texas Children's Hospital
Baylor College of Medicine

* **Arthur L. Beaudet, M.D.** pg. 26

Professor
Department of Molecular and Human Genetics & Pediatrics
Baylor College of Medicine

Karl-Dimiter Bissig, M.D., Ph.D. pg. 27

Assistant Professor
Center For Cell And Gene Therapy
Stem Cells and Regenerative Medicine Center
Department of Molecular and Cellular Biology
Baylor College of Medicine

***Robert Britton,** pg. 28

Professor
Department of Molecular Virology and Microbiology
Baylor College of Medicine

* **Douglas G. Burrin, Ph.D.** pg. 29

Professor
Children's Nutrition Research Center
Director, Fellowship Research Training
Gastroenterology, Hepatology and Nutrition
Department of Pediatrics
Baylor College of Medicine

Beth A. Carter, M.D. pg. 30

Associate Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Director of Intestinal Rehabilitation Clinic
Texas Children's Hospital
Baylor College of Medicine

* **Lawrence C. Chan, M.B.,B.S., D.Sc** pg. 31

Professor
Division of Diabetes, Endocrinology, and Metabolism
Betty Rutherford Chair in Diabetes Research , Director
Diabetes Research Center Chief
Baylor College of Medicine

Eric Chiou, M.D. pg. 32

Assistant Professor
Departments of Pediatrics, Gastroenterology
Baylor College of Medicine

Bruno P. Chumpitazi, M.D., M.P.H. pg. 33

Assistant Professor
Department of Pediatrics
Director, Neurogastroenterology and Motility Program
Texas Children's Hospital
Baylor College of Medicine



FACULTY

*** Indicates Training Grant Mentor**

*** Margaret E. Conner, Ph.D.** pg. 34

Associate Professor
Department of Molecular Virology and Microbiology & Immunology
Baylor College of Medicine

*** Hashem B. El-Serag, M.D., M.P.H.** pg. 35

Professor
Chief, Gastroenterology and Hepatology Section
Department of Medicine
GI Section Chief, Michael E. DeBakey VA Medical Center
Director, Texas Medical Center Digestive Disease
Baylor College of Medicine

*** Mary K. Estes, Ph.D.** pg. 36

Professor
Cullen Endowed Chair of Molecular and Human Virology
Departments of Molecular Virology and Microbiology, and Medicine-GI
Baylor College of Medicine

Milton J. Finegold, M.D. pg. 37

Professor
Departments of Pathology and Pediatrics
Texas Children's Hospital
Baylor College of Medicine

Douglas Fishman, M.D. pg. 38

Associate Professor
Department of Pediatrics
Gastroenterology, Endoscopy and Pancreaticobiliary Program (PBP)
Texas Children's Hospital
Baylor College of Medicine

Sanjiv Harpavat, M.D., Ph.D. pg. 39

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Baylor College of Medicine

Paula M. Hertel, M.D. pg. 40

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Baylor College of Medicine

*** Farook Jahoor, Ph.D.** pg. 41

Professor
Department of Pediatrics
Children's Nutrition Research Center
Baylor College of Medicine

Richard Kellermayer, M.D., Ph.D. pg. 42

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Children's Nutrition Research Center
Baylor College of Medicine

FACULTY

* Indicates Training Grant Mentor

*** Brendan H. L. Lee, M.D., Ph.D.** pg. 43
Robert and Janice McNair Endowed Chair and Professor
Chairman, Department of Molecular and Human Genetics
Baylor College of Medicine

Daniel Leung, M.D. pg. 44
Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Department of Viral Hepatitis Clinic
Texas Children's Hospital
Baylor College of Medicine

*** Lenard M. Lichtenberger, Ph.D.** pg. 45
Professor
Department of Integrative Biology and Pharmacology
University of Texas Medical School at Houston

Tamir Miloh pg. 46
Associate Professor
Director of Pediatric Liver Center
Baylor College of Medicine

*** David D. Moore, Ph.D.** pg. 47
Professor
Department of Molecular and Cellular Biology
Baylor College of Medicine

***Marc Rhoads,** pg. 48
Professor
Section Chief, Pediatric Gastroenterology
Fellowship Program Director
University of Texas Health Sciences Center at Houston

***Tor Savidge** pg. 49
Associate Professor
Texas Children's Microbiome Center
Department Pathology and Immunology
Baylor College of Medicine

***Benjamin Shneider** pg. 50
Professor
Section Chief, Gastroenterology, Hepatology and Nutrition
Department of Pediatrics
Baylor College of Medicine

***Noah Shroyer** pg. 51
Associate Professor
Section of Gastroenterology and Hepatology
Department of Medicine
Baylor College of Medicine

*** Robert J. Shulman, M.D.** pg. 52
Professor
Director, Center for Pediatric Abdominal Pain Research
Director, NIH T32 Training Grant in Pediatric Gastroenterology Research
Children's Nutrition Research Center
Gastroenterology, Hepatology and Nutrition
Department of Pediatrics
Baylor College of Medicine

FACULTY

* Indicates Training Grant Mentor

* **Betty L. Slagle, Ph.D.**

Associate Professor
Department of Molecular Virology and Microbiology
Assistant Director, Center for AIDS Research
Baylor College of Medicine

pg. 53

* **C. Wayne Smith, M.D.**

Professor
Department of Pediatrics
Director of Leukocyte Biology
Children's Nutrition Research Center
Baylor College of Medicine

pg. 54

Mary Tessier, M.D.

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Baylor College of Medicine

pg. 55

* **Sundararajah Thevananther, Ph.D.**

Associate Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Baylor College of Medicine

pg. 56

* **James Versalovic, M.D., Ph.D.**

Professor
Department of Pathology & Immunology
Vice Chair of Molecular Pathology and Omics
Head, Department of Pathology
Pathologist-in-Chef
Director Texas Children's Hospital

pg. 57

* **Huda Y. Zoghbi, M.D.**

Professor
Department of Molecular and Human Genetics,
Pediatrics, Neurology, and Neuroscience
Director, Jan and Dan Duncan Neurological
Research Institute at Texas Children's Hospital
Baylor College of Medicine

pg. 58



Childhood Obesity and Community Intervention



SARAH BARLOW

Associate Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Director of Obesity Center
Texas Children's Hospital

Recent Publications

Kelly AS, Barlow SE, Rao G, Inge TH, Hayman LL, Steinberger J, Urbina EM, Ewing LJ, Daniels SR; Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. *Circulation*. 2013 8;128:1689-712

Huang JS, Barlow SE, Quiros-Tejeira RE, Scheimann A, Skelton J, Suskind D, Tsai P, Uko V, Warolin JP, Xanthakos SA; NASPGHAN Obesity Task Force. Childhood obesity for pediatric gastroenterologists. *J Pediatr Gastroenterol Nutr*. 2013;56:99-109.

Pemberton VL, McCrindle BW, Barkin S, Daniels SR, Barlow SE, Binns HJ, Cohen MS, Economos C, Faith MS, Gidding SS, Goldberg CS, Kavey RE, Longmuir P, Rocchini AP, Van Horn L, Kaltman JR. Report of the National Heart, Lung, and Blood Institute's Working Group on obesity and other cardiovascular risk factors in congenital heart disease. *Circulation*. 9;121:1153-9, 2010.

Skelton JA, Cook SR, Auinger P, Klein JD, Barlow SE. Prevalence and trends of severe obesity among US children and adolescents. *Acad Pediatr*. 9:322-9, 2009.

Barlow SE. Databases and diagnosis of obesity: pitfalls and potential of using ICD-9 codes. *J Pediatr*. 54:315-7, 2009.

Barlow SE and the Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity; summary report. *Pediatrics*. 120:S164-192, 2007.

The focus of my research is the care of childhood obesity, especially in the community healthcare setting. Recent studies demonstrated the ability of primary care pediatricians to recognize childhood overweight and obesity. This recognition was not associated with use of body mass index (BMI) except when BMI levels were modestly elevated. Two qualitative studies, with pediatricians and with parents of overweight and obese children, were formative in developing a pilot project aimed at increasing a parent's desire to improve their child's eating and physical activity routines. This project activates parents before well-child visits to seek guidance during the visit on their child's eating or activity behaviors and facilitates semi-tailored advice from the provider.

The Obesity Center completed a pilot project demonstrating effectiveness of a community after-school program through the Houston Parks and Recreation Program. These data are published, and a larger, multi-center trial has been funded. A second research project focuses on the effect of a two-week residential summer camp program for weight loss. A pilot project demonstrated effectiveness, and a larger program is planned.

Future work will aim at linking primary care interventions with community programs.

Email: sbarlow@bcm.edu



ARTHUR L. BEAUDET

Neuronal Carnitine Deficiency as a Risk Factor for Autism

Professor
Department of Molecular and Human Genetics & Pediatrics
Baylor of College Medicine

Recent Publications

Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, Braxton A, Beuten J, Xia F, Niu Z, Hardison M, Person R, Bekheirnia MR, Leduc MS, Kirby A, Pham P, Scull J, Wang M, Ding Y, Plon SE, Lupski JR, Beaudet AL, Gibbs RA, Eng CM. "Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders." *N Engl J Med.* 2013;369:1502-11.

Schaaf CP, Gonzalez-Garay ML, Xia F, Potocki L, Gripp KW, Zhang B, Peters BA, McElwain MA, Drmanac R, Beaudet AL, Caskey CT, Yang Y. "Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism." *Nat Genet.* 2013;45:1405-8.

Beaudet AL. "The utility of chromosomal microarray analysis in developmental and behavioral pediatrics." *Child Dev.* 2013;84:121-32.

Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, Savage M, Platt LD, Saltzman D, Grobman WA, Klugman S, Scholl T, Simpson JL, McCall K, Aggarwal VS, Bunke B, Nahum O, Patel A, Lamb AN, Thom EA, Beaudet AL, Ledbetter DH, Shaffer LG, Jackson L.

"Chromosomal microarray versus karyotyping for prenatal diagnosis." *N Engl J Med.* 2012 December 6;367:2175-84.

Meng L, Person RE, Beaudet AL. "Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a." *Hum Mol Genet.* 2012 July 1;21:3001-12.

Bi W, Breman A, Shaw CA. "Neuroscience. Preventable forms of autism?." *Science.* 2012 October 19;338:342-3.

We have described a novel inborn error of carnitine biosynthesis caused by deficiency of the X-linked TMLHE gene. This deficiency is present in 1 in 350 control males and is a risk factor for autism. This has led us to hypothesize that neuronal carnitine deficiency is a risk factor in a subset of autism patients. We suggest that abnormalities of carnitine metabolism including low dietary intake, renal loss, impaired transport, or defective synthesis may be important in up to 10-20% of autism cases, especially in males with a normal physical examination and normal MRI of the brain. Thus some cases of autism may be preventable or treatable through dietary supplementation with carnitine.

Our laboratory is studying the role of epigenetics and de novo and inherited mutations in human disease with particular emphasis on genomic imprinting and its role in Prader-Willi syndrome (PWS), Angelman syndrome (AS), and autism. Genomic imprinting is the phenomenon of differential expression of the two alleles at an autosomal locus based on their parent of origin; usually one allele is expressed and the other silenced. PWS and AS are distinct human disorders characterized by neurobehavioral abnormalities and intellectual disability. They are caused by deficiency of paternally (PWS) or maternally (AS) expressed genes within chromosome 15q11-q13. Our laboratory has contributed to identification of molecular defects causing PWS and AS, identified the UBE3A locus encoding E6-AP ubiquitin-protein ligase as the AS gene, and made numerous mouse models related to PWS and AS. We are currently exploring the use of oligonucleotides in mice to knockdown the antisense transcript for UBE3A to unsilence expression of the sense transcript from the paternal chromosome as a treatment for Angelman syndrome.

The lab is also focused on the clinical implementation of new molecular methods for genetic diagnosis including the use of chromosomal microarray analysis (CMA), whole exome and whole genome sequencing, and cell-based noninvasive prenatal diagnosis. We have a special focus on analysis of deletions of chromosome 15q13.3 that can cause intellectual disability, autism, schizophrenia, epilepsy, and aggressive behavior. This has led to detailed genotyping for the CHRNA7 gene which maps to 15q13.3 and encodes a neuronal nicotinic acetylcholine receptor, which we believe is important in genetic causes of neurobehavioral disorders.

Email: abeaudet@bcm.edu



Liver Disease and Human Disease Modeling

Assistant Professor
Center For Cell And Gene Therapy
Stem Cells and Regenerative Medicine Center
Department of Molecular and Cellular Biology
Baylor College of Medicine

KARL-DIMITER BISSIG

Recent Publications

Billioud G., Kruse R.L., Carrillo M., Gao D., Kim A., Chen L.L., McCaleb M.L., Crosby J.R., Hamatake R., Hong Z., Garaigorta U., Swayze E., Bissig K.D., Wieland S.W. In vivo Reduction of Hepatitis B Virus Antigenemia and Viremia by Antisense Oligonucleotides J Hepatol. 2016 ;64:781-9.

Bissig-Choisat B., Wang L., Legras X., Pradip K.S., Chen L., Bell P., Pankowicz F.P., Hill M.C., Barzi M., Kettlun Leyton C., Eastwood L.C., Kruse R.L., Himes R.W., Goss J.A., Wilson J.M., Chan L.L., Lagor W.R. and Bissig K.D. Development and Rescue of Human Familial Hypercholesterolemia in a Xenograft Mouse Model. Nature Communications 2015, 17;6:7339.

Shih Y.M., Sun C.P., Chou H.H., Wu T.H., Chen C.C., Wu P.Y., Chen Y.C., Bissig K.D. Tao M.H. Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice. Scientific Reports 2015, 20;5:15259.

Lin F, Marcelo KL, Rajapakshe K, Coarfa C, Dean A, Wilganowski N, Robinson H, Sevick E, Bissig KD, Goldie LC, Means AR, York B. The camKK2/camKIV relay is an essential regulator of hepatic cancer. Hepatology. 2015 ;62(2):505-20

Dr. Dimi Bissig's group is interested in liver disease, ranging from viral hepatitis to metabolic liver disease and liver cancer. During his postdoc at the Salk Institute (2005-2011), he developed a new human liver chimeric mouse model (FRG (Fah^{-/-} Rag^{-/-}/Il2rg^{-/-}) mouse). In his own lab at Baylor, he created the first xenograft model for metabolic liver disease and a new liver cancer model, both of which faithfully mimic human disease. These humanized mouse models will help to advance and improve experimental therapies for liver disease.

Metabolic liver disease

By transplanting diseased human hepatocytes from a metabolic disease patient (familial hypercholesterolemia), we have managed to induce human disease in murine hosts and thereby have established the first xenograft model for human metabolic liver disease (Nature Commun. 2015). Further, we were able to rescue the disease phenotype with an experimental gene therapy. We are currently generating other xenograft models for human metabolic diseases and exploring experimental therapies.

Pediatric liver cancer

Pediatric liver cancer is a rare but serious disease whose incidence is rising and for which the therapeutic options are limited. Development of more targeted, less toxic therapies is hindered by the lack of an experimental animal model that captures the heterogeneity and metastatic capability of these tumors. We have recently established patient-derived tumor xenografts (PDTX) recapitulated the histologic, genetic, and biological characteristics—including the metastatic behavior—of the corresponding primary tumors (manuscript under review). We utilize this unique patient derived xenograft tumor model and combine it with a powerful mass spectrometry based screening method (proximal fluid proteomics) to analyze the secretome of human liver cancer. We are currently evaluating a list of differentially expressed and secreted proteins. Some of the proteins are novel and poorly characterized while others have been previously associated with other malignancies.

The goal of this study is to identify new biomarkers for early detection and risk-stratification.

Hepatitis B Virus (HBV)

Dr. Bissig established a replication system for Hepatitis B and C Virus in human liver chimeric FRG mice (J Clin Invest. 2010), which can be used to test new antiviral therapies. The Bissig lab is currently evaluating novel and alternative approaches against HBV in human liver chimeric mice and other model systems of HBV.

Other liver projects

Induced pluripotent stem (iPS) cells are a promising source for autologous cell therapy in the liver. We have generated multiple lines of iPS cells from metabolic liver disease fibroblasts and successfully corrected the underlying genetic defect by homologous recombination. We are currently working on more efficient ways to differentiated iPS cell derived cells, which is the major limitation for cell therapy in the liver.

The Bissig lab is extremely collaborative and open to new projects. We have shared humanized mice with multiple groups locally and internationally, resulting in fruitful collaborations (see publications)

Techniques/Methods in the Bissig lab:

- Human hepatocyte isolation and transplantation into FRG mice
- Gene therapy/virology techniques (virus preparation, titering, infections, etc.)
- Human and mouse induced pluripotent stem cell culture
- Stem cell targeting and generation of transgenic mouse models
- CRISPR/Cas9 genome engineering in TC and in vivo.
- Standard molecular biology techniques (cloning, DNA/RNA/protein work)

Email: Bissig@bcm.edu



ROBERT BRITTON

Therapeutic Microbiology

Professor
Department of Molecular Virology and Microbiology
Baylor College of Medicine

Recent Publications

Collins J, Auchtung JM, Schaefer L, Eaton KA, Britton RA. Humanized microbiota mice as a model of recurrent *Clostridium difficile* disease. *Microbiome*. 2015 Aug 20;3:35. doi: 10.1186/s40168-015-0097-2.

van Pijkeren JP, Britton RA. Precision genome engineering in lactic acid bacteria. *Microb Cell Fact*. 2014 Aug 29;13 Suppl 1:S10. doi: 10.1186/1475-2859-13-S1-S10. Review.

Robinson CD, Auchtung JM, Collins J, Britton RA. Epidemic *Clostridium difficile* strains demonstrate increased competitive fitness compared to nonepidemic isolates. *Infect Immun*. 2014 ;82:2815-25.

Britton RA, Irwin R, Quach D, Schaefer L, Zhang J, Lee T, Parameswaran N, McCabe LR. Probiotic *L. reuteri* treatment prevents bone loss in a menopausal ovariectomized mouse model. *J Cell Physiol*. 2014 Nov;229(11):1822-30. doi: 10.1002/jcp.24636.

Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. *Gastroenterology*. 2014;146:1547-53. Review.

Therapeutic Microbiology Laboratory. The Britton laboratory is interested in the role of microbes in health and disease, with a focus on identifying microbes with therapeutic properties for a variety of ailments. We use bacterial genetics, genomics, microbial ecology, and physiology to investigate individual microbes and microbial community structure and function.

1. The role of intestinal bacteria in health and disease. Recent work into the role of intestinal bacteria in a variety of disease states including inflammatory bowel disease, obesity, and diabetes has established a clear link between these bacteria and our health. The Britton laboratory is focused on two areas of research in this area: the role of probiotic bacteria in treating disease and the role of the intestinal microbiota in preventing pathogen invasion.

Probiotic *Lactobacillus reuteri*. Much of our work focuses on characterizing how different strains of *Lactobacillus reuteri* impact various aspects of the host response including inflammation, bone health, pathogen invasion and intestinal function. We use a variety of in vitro and animal models to explore how *L. reuteri* impacts health. Our overall goals are to identify novel probiotic strains that can be used to prevent or ameliorate disease and to develop a platform for the delivery of biotherapeutics.

Microbiota and prevention of pathogen invasion. We are interested in understanding how the intestinal microbiota provides a barrier to incoming pathogens and how perturbations of the microbiota result in an established infection. We have focused most of our attention on the pathogen *Clostridium difficile*, which is the most common cause of antibiotic associated diarrhea and is quickly becoming the most common cause of nosocomial infections. We have developed mini-bioreactors and mice colonized with a human intestinal microbiota to address which members of the community are responsible for inhibiting *C. difficile* invasion. Our ultimate goal is to develop a probiotic cocktail derived from the human intestinal microbiota that will suppress *C. difficile* invasion.

Regulation of gut hormone production by the microbiota. Obesity and type 2 diabetes are emerging problems in the United States population, including young children. Our laboratory is screening next-generation probiotics for their ability to modulate gut hormone production in an effort to find microbes that can help individuals maintain a healthy weight.

2. Recombineering in lactic acid bacteria.

Recombineering technology allows for the precise genetic manipulation of bacterial chromosomes. Using single-stranded DNA (ssDNA) recombineering technology point mutations, small deletions, and small insertions can be recovered without the need for selection. We have now established non-selected recombineering in two lactic acid bacteria strains, *Lactobacillus reuteri* and *Lactococcus lactis*. We also have shown that recombineering can function in other Gram-positive bacteria as well. We can achieve average recombineering efficiencies of ~15% in *L. lactis*, which will now enable directed evolution of multiple chromosomal sites to be achieved simultaneously. Finally, we have also developed an efficient method for inserting genes stably into the chromosome of *L. reuteri*, which will enable the use of this human-derived organism to be used in the intestinal delivery of biotherapeutics and vaccines.



DOUGLAS G. BURRIN

Nutritional Regulation of Neonatal Gut and Liver Health and Disease

Professor
Department of Pediatrics
Children's Nutrition Research Center
Director, Fellowship Research Training
Gastroenterology, Hepatology and Nutrition

Recent Publications

Vlaardingerbroek H, Ng K, Stoll B, Benight N, Chacko S, Kluijtmans LA, Kulik W, Squires EJ, Olutoye O, Schady D, Finegold ML, van Goudoever JB, Burrin DG. New generation lipid emulsions prevent PNALD in chronic parenterally fed preterm pigs. *J Lipid Res.* 2014; 55:466-77.

Burrin DG, Ng K, Stoll B, Sáenz De Pipaón M. Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. *Adv Nutr.* 2014 ; 1;5:82-91.

Ghoneim N, Bauchart-Thevret C, Oosterloo B, Stoll B, Kulkarni M, de Pipaon MS, Zamora IJ, Olutoye OO, Berg B, Wittke A, Burrin DG. Delayed initiation but not gradual advancement of enteral formula feeding reduces the incidence of necrotizing enterocolitis (NEC) in preterm pigs. *PLoS One.* 2014; 19;9 (9):e106888.

Jensen ML, Thymann T, Ciliborg MS, Lykke M, Mølbak L, Jensen BB, Schmidt M, Kelly D, Mulder I, Burrin DG, Sangild PT. Antibiotics modulate intestinal immunity and prevent necrotizing enterocolitis in preterm neonatal piglets. *Am J Physiol Gastrointest Liver Physiol.* 2014;1;306:G59-71.

Sangild PT, Ney DM, Sigalet DL, Vegge A, Burrin D. Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges. *Am J Physiol Gastrointest Liver Physiol.* 2014; 15;307:G1147-68.

Jain AK, Stoll B, Burrin DG, Holst JJ, Moore DD. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. *Am J Physiol Gastrointest Liver Physiol.* 2012; 15;302:G218-24.

Our laboratory works on basic and translational projects designed to establish how nutritional support, enteral versus parenteral, effects gut and liver function and susceptibility to disease in early development. We have used the neonatal piglet to establish unique models of parenteral nutrition-associated liver disease (PNALD), necrotizing enterocolitis (NEC) and short-bowel syndrome (SBS) to address clinically -relevant problems in pediatric gastroenterology.

Current projects in the laboratory seek to identify the cellular and molecular mechanism that lead to PNALD and metabolic dysfunction associated with prematurity and neonatal parenteral nutrition (PN) support. Our recent studies show that chronic PN induces hepatic steatosis, cholestasis and insulin resistance in term and premature neonatal piglets. We are currently exploring how specific nutrients in commercial lipid emulsions alter the susceptibility to PNALD. We are exploring how nutrients affect interorgan and local cellular signaling pathways involved in hepatic lipid metabolism and bile acid homeostasis. We are also testing whether the adverse metabolic phenotype induced by PN is programmed and persists beyond the neonatal period and predisposes to adolescent fatty liver disease and type 2 diabetes.

Studies also are aimed at establishing the cellular and physiological functions of glucagon-like peptide 2 (GLP-2), an FDA-approved gut hormone currently in clinical trial for treatment of adult short-bowel syndrome. Past studies in TPN-fed piglets were first to show the trophic and vasoactive actions of GLP-2 in the neonatal gut. We identified the cellular co-localization of the GLP-2 receptor in enteric neurons with neurotransmitters. Current studies are aimed at establishing unique enterally-mediated signaling mechanisms that trigger enteroendocrine cell GLP-2 secretion and GLP-2 receptor function. We are also testing the efficacy of GLP-2 administration for prevention of NEC and treatment of SBS in premature piglet models.

We take an integrative experimental approach dictated by the research question to address relevant functions at the whole animal, tissue, cellular or molecular level. We use sophisticated metabolic, cell biological and molecular approaches, such as stable isotope metabolomics, laser-capture microdissection, gene microarray, and confocal microscopic imaging to identify the cellular localization of specific signals involved in the metabolism, proliferation and survival of relevant cell types, including mucosal epithelial cells and hepatocytes.

Email: dburrin@bcm.edu



BETH A. CARTER

Clinical Outcomes Omega 3 Fatty Acid Fish-Oil-Derived Lipid Emulsion for the Treatment of PN-Associated Cholestasis

Associate Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Director of Intestinal Rehabilitation Clinic
Texas Children's Hospital

Recent Publications

Willis TC, Carter BA, Rogers SP, Hawthorne KM, Hicks PD, Abrams SA. High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. *J Parenter Enteral Nutr* 34:32-37, 2010.

Carter BA, Karpen SJ. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. *Semin Liver Dis.* 27(3):251-8, 2007.

Carter BA, Prendergast DR, Taylor OA, Zimmerman TL, Furstenberg RV, Moore DD, Karpen SJ. Stigmasterol, a Soy Lipid-Derived Phytosterol, Is an Antagonist of the Bile Acid Nuclear Receptor FXR. *Pediatr Res.* 62(3):301-6, 2007.

Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. *Nat Clin Pract Gastroenterol Hepatol.* 4(5):277-87, 2007.

Taylor OA, Popek EJ, Albright JT, Barshes NR, Goss JA, Carter BA. Oropharyngeal plasmacytic hyperplasia in a post-liver transplant recipient: morphologic and histologic signs. *Liver Transpl.* 13 (1):170-2, 2007.


Barshes NR, Carter BA, Karpen SJ, O'Mahony CA, Goss JA. Isolated orthotopic liver transplantation for parenteral nutrition-associated liver injury. *JPEN.* 30(6):526-9, 2006.

The focus of my research is to provide an understanding of TPN (Total Parenteral Nutrition)-associated cholestasis. TPN is a form of intravenous nutrition given to patients who are unable to feed via the normal enteral route due to prematurity, intestinal surgery, or other medical condition. The administration of TPN has been life-saving, but in certain settings (e.g. the premature infant with short bowel syndrome), it has been associated with the rapid development of end-stage liver disease. Risk factors for TPN-associated "cholestasis," or slow bile flow, include prematurity, infection, bowel dysfunction, and length of TPN administration. The cause of this TPN-associated liver disease is unknown. We are focused on unraveling a molecular etiology for this disease that will, in turn, help identify anti-cholestatic therapeutic targets to treat this condition that is primarily seen in the pediatric population.

My laboratory research has focused on a component of the lipid fraction of TPN, stigmasterol. This compound is a phytosterol, is structurally similar to bile acids, and is an obligate component of Intralipid®. We used quantitative PCR in both mouse and human liver cell lines to show that this compound antagonizes bile acid activation of the nuclear receptor FXR (Farnesol X Receptor). We know from FXR knockout studies performed by previous investigators, that FXR is a crucial player in maintaining hepatocyte integrity and bile flow. Specifically, FXR $-/-$ mice fed a cholic acid diet die of hepatic necrosis and liver failure within 5 days of bile acid feeding, while FXR $+/+$ remain unharmed (Sinal et al, *Cell*, 2000). We are currently exploring and furthering our preliminary data that stigmasterol (and, more broadly all phytosterols) are FXR antagonists that induce a "chemical knockout" of hepatocyte integrity in the setting of parenteral nutrition.

In 2007, I began a new collaboration with Texas Children's neonatologists, dietitians, and pharmacists that explores the safety and efficacy of an Omega 3 fish oil-derived intravenous lipid emulsion (Omegaven®) administration to infants with TPN-associated cholestasis. This study allows previous ideas and findings from the "bench" to be brought to the bedside." I am the Center PI for a recently submitted multicenter study of pediatric intestinal failure (Pediatric Intestinal Failure Consortium, "PIFCon"). The aim of this consortium is to retrospectively look at management trends for intestinal failure and then collaborate amongst the various centers to test various medical interventions, therapies, and outcomes.

Email: bac@bcm.edu



LAWRENCE C. CHAN

Pathophysiology, Complications and Gene Therapy of Type 1 and Type 2 Diabetes

Professor

Division of Diabetes, Endocrinology, and Metabolism
Betty Rutherford Chair in Diabetes Research, Director
Diabetes Research Center Chief
Baylor College of Medicine

RECENT PUBLICATIONS:

Buras ED, Yang L, Saha P, Kim J, Mehta PC, Yang Y, Hilsenback S, Kojima H, Chen W, Smith CW, Chan L (2015) Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice. *FASEB J* 29, 3537–3548.

Li R, Buras E, Lee J, Liu R, Liu V, Espiritu C, Ozer K, Thompson B, Nally L, Yuan G, Oka K, Chang B, Samson S, Yechool V*, Chan L* (2015) Gene therapy with Neurogenin3, Betacellulin and SOCS-1 reverses diabetes in NOD mice. *Gene Therapy* (in press).

Urabe H, Terashima T, Lin F, Kojima H, Chan L (2015) Bone marrow-derived TNF- α causes diabetic neuropathy. *Diabetologia* 58:402-410.

Poungvarin N, Chang B, Imamura M, Chen J, Moolsuwan K, Sae-Lee C, Li W, Chan L (2015) Genome-wide analysis of ChREBP binding sites on male mouse liver and white adipose chromatin. *Endocrinology* 2015 Jun; 156(6):1982-94.

Oka K, Mullins C, Kushwaha R, Leen A, Chan L (2015) Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon-catheter hepatic delivery of helper-dependent adenoviral vector. *Gene Therapy* 22: 87-95

Imamura M, Chang BH-J, Kohjima M, Li M, Hwang B, Taegtmeier H, Harris RA, Chan L (2014) MondoA deficiency enhances sprint performance in mice. *Biochemical J* 464: 35-48.

Kojima H, Kim J, Chan L (2014) Emerging roles of hematopoietic cells in the pathobiology of diabetic complications. *Trends Endo Metab* 25: 178-187.

Kohjima M, Tsai T, Tackett BC, Thevananther S, Li L, Chang BH-J, Chan L (2013) Delayed liver regeneration after partial hepatectomy in adipose differentiation-related protein-null mice. *J Hepatol* 59: 1246-1254.


Chen W, Chang B, Wu X, Li L, Sleeman M, Chan L (2013) Inactivation of Plin4 downregulates Plin5 and reduces cardiac lipid accumulation in mice. *Am J Physiol Endocrinol Metab* 304: E770-9.

Dr. Chan's laboratory is active in the following research areas: (1) Type 1 and type 2 diabetes and the metabolic syndrome, molecular biology and pathogenesis and (2) Somatic gene therapy and other molecular therapies for the treatment of diabetes and obesity.

Dr. Chan is interested in the molecular pathology of hyperglycemia and diabetic complications. He and his colleagues first described the appearance of insulin-producing cells in multiple extrapancreatic tissues in diabetes. The laboratory showed that the insulin-producing cells are derived from bone marrow cells that migrate from the bonemarrow to multiple tissues, including the liver and adipose tissues. They may retain their bone marrow cell characteristics or they may fuse with the local cells in various tissues and organs. His laboratory further showed that the fusion of these abnormal bone marrow derived cells with nerve cells is an important factor in diabetic neuropathy. The Chan laboratory developed a novel therapy for a type 1 diabetes model in mice.

They showed that gene therapy-mediated delivery of a transcription factor, Neurog3 (together with an islet growth factor, betacellulin) to the liver of diabetic mice leads to the development of new islets in the liver. These islets produce insulin and other islet hormones, leading to complete correction of the diabetes. The gene therapy-induced islet neogenesis strategy that "cures" type 1 diabetes in mice is significant, not only for its potential as a new treatment, but also because it is the first time a single transcription factor has been shown to lead to the biogenesis of a complete organ (endocrine pancreas) in an adult animal. His laboratory showed that the newly formed β cells were derived from adult stem cells in the liver by a process consistent with transdetermination. Glis3 is a krüppel-like zinc finger transcription factor that is expressed in essentially all cells in the body. The factor is expressed at high levels in pancreatic β cells. Genome wide association studies among adult populations have found a strong association of Glis3 polymorphisms in type 1 and type 2 diabetes. Intriguingly, mutations in Glis3 have been reported to cause a syndrome of neonatal diabetes. The Chan laboratory is interested in the developmental biology of the endocrine pancreas, particularly in the molecular pathology of the neonatal diabetes syndrome. They found that Glis3 regulates pancreatic islet growth and differentiation during fetal development in mice. Moreover, they showed that Glis3 is required for normal insulin gene expression; importantly, it is indispensable for normal β cell function and β cell mass maintenance in adult animals. His group is pursuing the molecular characterization of the action of Glis3 in pancreatic β cell biology and function.

In the area of metabolic syndrome and type 2 diabetes, the Chan laboratory is investigating the role of different fat cell proteins in carbohydrate and lipid homeostasis. They produced mutant mice, including those with inactivated perilipin and adipocyte differentiation related protein (ADRP), as well as the gene for multiple other lipid droplet proteins, to dissect the biochemical pathways that regulate lipolysis and energy metabolism in vivo. He is interested in the role of the lipid droplet proteins in the molecular pathogenesis of lipodystrophy and type 2 diabetes. They found that ADRP determines the lipid droplet protein composition of lipid droplets, including proteins that actively participate in the regulation of ER stress and autophagy. In other words, lipid droplet proteins control their own existence.



ERIC CHIOU

Disorders of Esophageal Motility

Assistant Professor
Departments of Pediatrics, Gastroenterology
Baylor College of Medicine

Recent Publications

E Chiou, R Rosen, H Jiang, S Nurko. Diagnosis of supra-esophageal gastric reflux: Correlation of oropharyngeal pH with esophageal impedance monitoring for gastroesophageal reflux. *Neurogastroenterology and Motility*; 23: 717-e326, 2011.

WW Chan, E Chiou, KL Obstein, AS Tignor, TL Whitlock. The Efficacy of Proton Pump Inhibitors for Treatment of Asthma: a Meta-Analysis. *Arch Int Med*, 171(7):620-629, 2011.

E Chiou, Nurko, S. Functional abdominal pain and irritable bowel syndrome in children and adolescents. *Therapy*, 8(3): 315-331, 2011.

E Chiou, R Rosen, S Nurko. The Impact of Different pH Criteria on Dual Probe pH-Monitoring in the Evaluation of Supraesophageal Gastric Reflux in Children. *J Pediatr Gastroenterol Nutr*. 52(4):399-403, 2011.

E Chiou, S Nurko. Management of Functional Abdominal Pain and Irritable Bowel Syndrome in Children and Adolescents. *Expert Rev Gastroenterol Hepatol*. 4(3):293-304, 2010.

EH Chiou. Poetry in Motion: examining the role of peroral endoscopic myotomy in children. *Gastrointest Endosc*. 2015 Jan;81(1):101-3

EH Chiou, J Ongkasuwan. Delayed identification of proximal tracheoesophageal fistula. *J Pediatr Gastroenterol Nutr*, 2014 May;58(5):e45

The focus of my research is on disorders of esophageal motility in children. Gastroesophageal reflux disease (GERD) is considered one of the most common gastrointestinal motility disorders, affecting an estimated 1.8% to 8.2% of all children and adolescents worldwide. We now understand that the majority of acid reflux occurs as a result of transient relaxations of the lower esophageal sphincter. Despite the prevalence of GERD, there are still many unanswered questions regarding its diagnosis and management.

I am particularly interested in studying extra-intestinal manifestations of GERD in the airways and lungs. Although varied conditions such as asthma, otitis media, sleep apnea and chronic laryngitis have all been linked to GERD, there is still poor understanding regarding the pathogenesis of these complications. A major reason for this is the lack of an accurate and reliable tool for the diagnosis of reflux in the anatomic areas above the esophagus. Investigations have looked at the accuracy of measuring changes in pH in the proximal esophagus and posterior oropharynx, as well as the use of esophageal impedance monitoring to measure both acid and non-acid reflux. Current projects are looking at the role of gastroesophageal reflux in affecting changes to the human oral microbiome and its relationship to dental lesions. In addition, we are studying the use of transmission electron microscopy to look for ultrastructural changes in the esophageal epithelium known as dilated intercellular spaces (DIS) which have been associated with GERD and alterations in epithelial permeability.

My second area of investigation includes evaluating the use of high-resolution manometry techniques for the diagnosis of esophageal motility disorders in general. We have compared the use of this new modality to conventional techniques and are interested in understanding how these new measures of motility can be used to improve diagnosis, management and clinical outcomes.

Email: ehchiou@bcm.edu



BRUNO CHUMPITAZI

Clinical and Translational Research in Childhood Motility and Functional Gastrointestinal Disorders

Associate Professor
Department of Pediatrics
Director, Neurogastroenterology and Motility Program
Texas Children's Hospital

Recent Publications

Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ "Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with irritable bowel syndrome" *Aliment Pharmacol Ther.* 2015 42(4):418-27.

Wong GK, Shulman RJ, Chumpitazi BP "Gastric Emptying Scintigraphy Results in Children are Affected by Age, Anthropometric Factors, and Study Duration" *Neurogastroenterol Motil* 2015 27(3):356-362.

Wong GK, Shulman RJ, Malaty HM, Czyzewski D, Seghers VJ, Thompson D, Chumpitazi BP "Relationship of Gastrointestinal Symptoms and Psychosocial Distress to Gastric Retention in Children Undergoing Gastric Emptying Scintigraphy" *J Pediatr.* 2014 165(1):85-91.e1

Chumpitazi BP, Hollister EB, Oezguen N, Tsai CM, McMeans A, Luna RA, Savidge TC, Versalovic J, Shulman RJ "Gut Microbiota Influences Low Fermentable Substrate Diet Efficacy in Children with Irritable Bowel Syndrome" *Gut Microbes* 2014 5(2):165-75

Carlson M, Moore C, Tsai CM, Shulman RJ, Chumpitazi BP "Child and Parent Perceived Food-Induced Gastrointestinal Symptoms and Quality of Life in Children with Functional Gastrointestinal Disorders" *J Acad Nutr Diet.* 2014 14(3):403-13

Wong GK, Chiou EH, Shulman RJ, Chumpitazi BP "Decreased Relative Diagnostic Yield of Esophagogastroduodenoscopy in Children with Gastroparesis" *J Clin Gastroenterol.* 2014 48(3): 231-5.

Chumpitazi BP, Lane MM, Czyzewski DI, Shulman RJ "Initial Creation and Evaluation of a Pediatric Stool Form Scale" *J Pediatr.* 2010; 157(4):594-7

Chumpitazi BP, Fishman S, Nurko S. "Long Term Clinical Outcome After Botulinum Toxin Injection in Children with Non-Relaxing Internal Anal Sphincter" *Am J Gastroenterol.* 2009;104(4):976-983

Our group's research is focused on childhood gastrointestinal functional and motility disorders. These disorders include irritable bowel syndrome (IBS), functional dyspepsia, gastroparesis, and constipation. We have several areas of investigation relating to diet and IBS, diet and gut microbiome interactions in symptom generation in childhood IBS, and evaluation of diagnostic and therapeutic modalities for childhood gastroparesis, functional dyspepsia, and defecation disorders.

The Role of Diet and the Diet-Gut Microbiome Interaction in Childhood IBS

We seek to elucidate the role of diet in generating symptoms (e.g. abdominal pain) in children with IBS. Our efforts have ranged from focus groups and questionnaires to pilot dietary interventions and randomized clinical trials. Within our randomized controlled trials we have focused on the low fermentable oligosaccharide disaccharide monosaccharide and polyols (FODMAP) diet. In conjunction with the Texas Children's Microbiome Center we use bacterial metagenomics and metabolomics to characterize the role of diet-microbiome interactions in generating childhood IBS symptoms. New projects include a specific focus on fructans (one of the FODMAP carbohydrates), biopsy studies, guided imagery treatment, human and microbiome carbohydrate enzyme genetics, and expansion of our work to elucidate diet-microbiome interactions in healthy children.

Diagnostic and Therapeutic Modalities for Childhood Gastroparesis and Functional Dyspepsia

Our group investigates the role of diagnostic testing such as endoscopy and gastric emptying scintigraphy in children with functional dyspepsia and gastroparesis. We have evaluated 4 hour gastric emptying scintigraphy studies in children and have evaluated the relationship of gastric retention to dyspepsia symptoms. New projects in this area include a long-term registry of children with these disorders, biopsy studies, evaluation of guided imagery as a therapy, and evaluation of electrotherapy in children with these disorders.

Diagnostic and Therapeutic Modalities for Childhood Defecation Disorders

Our group also investigates the role of diagnostic modalities such as anorectal manometry and stool form scales in children with defecation disorders. Stool form scales in which a child selects what his/her stool appears like is helpful clinically and in the clinical research setting. We are also actively investigating the role of therapies such as BoTox injections and physical therapy for children with these disorders. New projects in this area include head-to-head comparisons of stool form scales to determine the best one for children and evaluation of electrotherapies in children with chronic constipation.

Email: chumpita@bcm.edu



MARGARET E. CONNER

Pathogenesis of Intestinal Viral Infections

Associate Professor

Department of Molecular Virology and Microbiology & Immunology

Recent Publications

Williams, K, Koyama T, Schulz D, Kaluza GL, Pautler RG, Weisbrodt N, Conner ME. Use of Fluoroscopy to Study In Vivo Motility in Mouse Pups. *JPGN*. 2011, 52:679-685. doi.org/10.1097/MPG.0b013e31820a0e86

Blutt SE, Miller AD, Salmon SL, Metzger DW, Conner ME. IgA is important for clearance and critical for protection from rotavirus infection. *Mucosal Immunology*, 2012, 5:712-719 [Epub ahead of print Jun 27 2012] PMID: PMC3461240

Lopatin U*, Blutt SE*, Conner ME, Kelsall B. Lymphotoxin alpha-deficient mice clear persistent rotavirus infection after local generation of mucosal IgA. *J. Virol.* 2013, 87:524-30. doi: 10.1128/JVI.01801-12. Epub 2012 Oct 24 (*co-first author) PMID: 23097456

Miller AD, Blutt SE, Conner ME. FoxP3+ regulatory T cells are not important for rotavirus clearance or the early antibody response to rotavirus. *Microbes Infect.* 2014; 16:67-72 doi: 10.1016/j.micinf.2013.09.004. [Epub ahead of print 2013] PMID:PMC3947018

Blutt SE, Conner ME. The Gastrointestinal Frontier: IgA and viruses. *Front Immunol.* 2013, Nov 28;4:402 PMID: PMC3842584

Killoran KE, Miller AD, Uray KS, Weisbrodt NW, Pautler RG, Goyert SM, van Rooijen N, Conner ME. Role of innate immunity and altered intestinal motility in LPS- and MnCl₂-induced intestinal intussusception in mice. *Am J Physiol: Gastro Liver, Mar;306(5):G445-53.* doi: 10.1152/ajpgi.00264.2013. Epub 2014 Jan 9 PMID:PMC3949022

The Conner laboratory focuses on the response of the host and microbiome to gastrointestinal pathogens. One theme of our research is the role of IgA in gastrointestinal mucosal defense against two enteric pathogens, rotavirus and *Clostridium difficile*. We use mouse models to identify the immunologic factors and underlying mechanisms of IgA induction and maintenance. We are also examining how rotavirus infection affects the intestinal microbiome. We are also exploring the mechanisms of rotavirus- and bacterial-induced intestinal intussusception.

Rotavirus is the most common cause of severe dehydrating diarrhea in children and results in the death of ~500,000 children yearly worldwide. Despite new efficacious vaccines, immune mechanisms that protect against rotavirus have yet to be well defined. We identified that intestinal IgA is critical for protection from rotavirus infection. polyclonally activates B cells in Peyer's patches in the intestine. We are now exploring the signaling pathways that induce IgA class switch recombination and current data support that rotavirus induces IgA by non-canonical signaling. Understanding the mechanisms by which this virus induces intestinal IgA and how this IgA is maintained will broaden our knowledge of IgA induction and regulation in the intestine and this information will be used to develop more effective mucosal vaccines and new methods of therapy. Our studies suggest that novel insights about intestinal immunity will be gained by defining basic pathways through which IgA is induced in the intestine in response to viral pathogens.

The first licensed rotavirus vaccine was withdrawn from the market because of an association with intestinal intussusception (ISS). Post-marketing surveillance data indicate that the currently licensed RotaTeq and RotaRix vaccines also pose an increased risk of ISS. We developed a mouse model to study rotavirus-associated ISS and obtained the first direct proof that rotavirus contributes to development of ISS. Induction of ISS is both virus dose- and replication-dependent. ISS is also associated with bacterial infections and we used a lipopolysaccharide (LPS) model of ISS to begin to define mechanisms of this complex process. LPS-ISS is initiated by innate immune signaling that requires TLR4 and phagocytes but may be independent of TNF- α , IL-6, and NO levels. Furthermore, alteration of intestinal motility, specifically, reduced intestinal contraction rate, is a key factor in the development of ISS. Multiple risk factors are associated with ISS in children that are also risk factors in the mouse models and we are exploring how these factors and rotavirus infection contribute to ISS.

Clostridium difficile (CD) is a gastrointestinal pathogen that is a major and increasing health care burden costing the United States an estimated 3 billion dollars/year. CD infection (CDI) is now the most common healthcare-associated infection. Mortality rates range from 5.7% to 15% with an estimated 7,752-20,000 deaths occurring annually from hospital onset CDI. CDI is a toxin-mediated disease in the large intestine. It has long been recognized clinically that immunosuppressed individuals, whether due to age, therapy with immunosuppressive drugs, or immunosuppressive infection, are at increased risk for CDI and relapsing CDI but the critical immunologic factors are not known. There is much indirect/correlative evidence supporting an important role of adaptive immunity to CDI. Using a mouse model, we are empirically probing the requirement for IgA and gut associated lymphoid tissue in adaptive immunity to CDI. Gaining a greater understanding of and identifying the key immunologic mediators of protection will contribute important insights to ongoing efforts to develop efficacious therapeutics and vaccines for CDI.

Email: mconner@bcm.edu



HASHEM B. EL-SERAG

Clinical Epidemiology and Outcomes of GI and Liver Disorders

Professor
Chief, Gastroenterology and Hepatology Section
Department of Medicine
Director, Texas Medical Center Digestive Disease
Baylor College of Medicine

Recent Publications

El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection. *Hepatology*. 63:2245, 2016

White DL, Richardson P, Tayoub N, Davila JA, Kanwal F, El-Serag HB. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-related Cirrhosis. *Gastroenterology*. 2015;149:1986-7.

Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. *Ann Intern Med*. 18;154:85-93, 2011.

Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. *Gastroenterology*. 140:1182-1188, 2011.

Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. *Gastroenterology*. 138:2260-6, 2010.

El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. *Arch Intern Med*. 167(18):1983-9, 2007.

The group at the Division of Clinical Epidemiology and Outcomes at the Houston Center for Quality of Care and Utilization, headed by Dr. El-Serag, examines several aspects of the epidemiology and outcomes of GI and liver disorders.

Dr. El-Serag's research agenda focuses on epidemiology and outcomes of digestive (esp. Barrett's esophagus) and liver diseases (esp. HCV and HCC). Dr. El-Serag is an internationally-recognized expert in the clinical epidemiology and comparative effectiveness of liver, esophageal and digestive disorders and their therapies. His seminal work on HCC published in *The New England Journal of Medicine* has been cited over 2,400 times. His recently completed NIH RC4 grant focused on patient-centered approaches to understanding the comparative effectiveness of screening and surveillance for Barrett's esophagus and esophageal adenocarcinoma. He and his collaborators are developing innovative comparative effectiveness research (CER) methods, e.g., improving the validity and reliability of secondary databases for CER, extraction of free-text data from electronic databases using natural language processing methods, and refining analytical methods for CER such as matched propensity score models and directed acyclic graphs. His group has assembled, through multiple R01 and VA funding, a single center based large two cohort: one of approximately 2200 patients (400 Barrett's cases, 1300 endoscopy non-BE controls, 500 primary care controls); and the second of 1100 patients with HCV infection, both cohort with extensive epidemiological, clinical and genetic information and multi-year follow up outcomes data. These datasets have served as frame work for mentored research projects. The group at the Division of Clinical Epidemiology and Outcomes at the Houston Center for Quality of Care and Utilization, headed by Dr. El-Serag, examines several aspects of the epidemiology and outcomes of GI and liver disorders.

Dr. El-Serag's research agenda focuses on epidemiology and outcomes of digestive (esp. Barrett's esophagus) and liver diseases (esp. HCV and HCC). Dr. El-Serag is an internationally-recognized expert in the clinical epidemiology and comparative effectiveness of liver, esophageal and digestive disorders and their therapies. His seminal work on HCC published in *The New England Journal of Medicine* has been cited over 2,400 times. His recently completed NIH RC4 grant focused on patient-centered approaches to understanding the comparative effectiveness of screening and surveillance for Barrett's esophagus and esophageal adenocarcinoma. He and his collaborators are developing innovative comparative effectiveness research (CER) methods, e.g., improving the validity and reliability of secondary databases for CER, extraction of free-text data from electronic databases using natural language processing methods, and refining analytical methods for CER such as matched propensity score models and directed acyclic graphs. His group has assembled, through multiple R01 and VA funding, a single center based large two cohort: one of approximately 2200 patients (400 Barrett's cases, 1300 endoscopy non-BE controls, 500 primary care controls); and the second of 1100 patients with HCV infection, both cohort with extensive epidemiological, clinical and genetic information and multi-year follow up outcomes data. These datasets have served as frame work for mentored research projects.

Email: hasheme@bcm.edu



Gastrointestinal Virus-Cell Interactions, Pathogenesis and Immunity

Professor

Cullen Endowed Chair of Molecular and Human Virology

Departments of Molecular Virology and Microbiology, and Medicine-GI

Baylor College of Medicine

MARY K. ESTES

Recent Publications

CCzakó R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. *Clin Vaccine Immunol.* 2015;22:221-8.

Zhang B, Chassaing B, Shi Z, Uchiyama R, Zhang Z, Denning TL, Crawford SE, Estes MK, Dermody TS, Ouyang W, Williams IR, Vijay-Kumar M, Gewirtz AT. Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. *Science.* 2014;14:346:861-5.

Foulke-Abel J, In J, Kovbasnjuk O, Zachos NC, Ettayebi K, Blutt SE, Hyser JM, Zeng XL, Crawford SE, Broughman JR, Estes MK, Donowitz M. Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. *Exp Biol Med.* 2014 Sep;239 (9):1124-34.

Patel NC, Hertel PM, Hanson IC, Krance RA, Crawford SE, Estes M, Paul ME. Chronic rotavirus infection in an infant with severe combined immunodeficiency: successful treatment by hematopoietic stem cell transplantation. *Clin Immunol.* 2012;142:399-401.

Finkbeiner SR, Zeng XL, Atmar RL, Shroyer NF, Estes MK. Stem cell-derived human intestinal organoids as an infection model for rotaviruses. *MBio.* 2012; 3;3:e00159-12.

Gladstone BP, Ramani S, Banerjee I, Muliyl J, Sarkar R, affar S, Gomara MI, Crawford SE, John J, Babji S, Estes MK, Kang G. Protection conferred by natural rotavirus infection against subsequent infection and disease in an Indian birth cohort. *NEJM.* 2011 28;365:337-46.

We are using viruses that infect distinct types of cells (enterocytes, crypt cells, M cells) in the GI tract as probes to learn about the biology, host response and gene expression of these cells. Our work on the molecular biology of GI viruses uses two viruses, rotaviruses, the major cause of diarrhea in children and animals worldwide, and noroviruses, the cause of almost all (>96%) outbreaks of epidemic gastroenteritis in all age groups. Most studies are multidisciplinary and involve in vitro and in vivo models of infection including studies in volunteers, animal models and novel ex vivo human intestinal mini-gut enteroid cultures. Our research program is divided into several areas including molecular analysis of GI viral-host interactions that affect pathogenesis and also include studies to develop strategies for mucosal immunization with non-replicating virus-like particles (VLPs), identification of intestinal glycan receptors for GI viruses, and understanding the stem cell response to infection. Cloning and sequencing the first human calicivirus genome from Norwalk virus (NV) led to development and use of new diagnostic assays that have resulted in changing our understanding of the natural history and epidemiology of infections with these viruses. Notably, NV and related viruses are now recognized as important causes of disease in children and in immunocompromised individuals, including transplant patients. Recombinant NV VLPs are a promising candidate vaccine. Recent identification of a correlate of protection and initial efficacy studies with promising results are stimulating norovirus vaccine development and field trials are being planned. Finally, the molecular basis of the restricted replication of Norwalk viruses to the GI tract of humans is being dissected by using the first infectious cDNAs of Norwalk virus in mammalian cells. Histo-blood group antigens are host susceptibility factors and the role of the innate immune response in blocking replication is being pursued.

Email: mestes@bcm.edu



Cholestatic and Neoplastic Liver Diseases in Children

Professor Emeritus
Departments of Pathology and Pediatrics
Texas Children's Hospital
Baylor College of Medicine

MILTON J. FINEGOLD

Recent Publications

Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim MS, Kim KH, Shneider BL, Finegold MJ, Muzny DM, Boerwinkle E, Lupski JR, Plon SE, Gibbs RA, Eng CM, Yang Y, Washington GC, Porteus MH, Berquist WE, Kambham N, Singh RJ, Xia F, Enns GM, Moore DD. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. *Nat Commun.* 2016; 18;7:10713.

Elevated copper impairs hepatic nuclear receptor function in Wilson's disease. Wooton-Kee CR, Jain AK, Wagner M, Grusak MA, Finegold MJ, Lutsenko S, Moore DD. 2015 Sep;125 (9):3449-60.

Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. Zhou S, Hertel PM, Finegold MJ, Wang L, Kerkar N, Wang J, Wong LC, Plon SE, Sambrotta M, Foskett P, Niu Z, Thompson RJ, Knisely AS. *Hepatology.* 2015 Apr 29. doi: 10.1002/hep.27872. [Epub ahead of print] No abstract available.

Dong B, Lee JS, Park YY, Yang F, Xu G, Huang W, Finegold MJ, Moore DD. Activating CAR and β -catenin induces uncontrolled liver growth and tumorigenesis. *Nat Commun.* 2015; 9;6:5944.

Harpavat S, Devaraj S, Finegold MJ. An infant with persistent jaundice and a normal newborn direct bilirubin measurement. *Clin Chem.* 2015; 61 (2):330-3.

Tarlow BD, Pelz C, Naugler WE, Wakefield L, Wilson EM, Finegold MJ, Grompe M. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. *Cell Stem Cell.* 2014; 6;15:605-18.

Dr Finegold is one of the Pathology directors of the NIDDK - sponsored Consortium on Childhood cholestatic liver disease (ChildREN). It is devoted to collaborative translational research on etiology, pathogenesis, and treatment of Extrahepatic Biliary Atresia, Alagille syndrome, Cystic fibrosis, Progressive familial intrahepatic cholestasis, Alpha 1-antitrypsin deficiency and Idiopathic Neonatal Hepatitis. Fifteen major medical institutions participate and the pathologists from each them meet 3x per year to review biopsies, explants and other specimens in order to establish diagnostic criteria and plan hypothesis-driven investigations, within the committee or as part of disease-oriented committees. His special interest is in "Idiopathic" Neonatal hepatitis.

Also, Dr Finegold has been the pathologist for the Children's Oncology Group Liver Tumor study group since 1986, for which he reviews all stage 1 and 2 hepatoblastomas in order to determine the need for chemotherapy, and all biopsies, resections or transplants as part of on-going research on treatment strategies.

Dr Finegold is Director of the Texas Medical Center Digestive Disease Center Molecular Morphology Core Laboratory, sponsored by the NIDDK. In this capacity, he acts as consultant to over 50 members of the Center and the young investigators and Fellows in their laboratories on the appropriate methods and procedures needed for their studies, as well as managing the actual work performed by the laboratory, and helping with images, interpretations and manuscript preparation.

Email: MJFINEGO@texaschildrens.org



Advanced Endoscopic Techniques and Pancreaticobiliary Diseases

Associate Professor
Department of Pediatrics
Gastroenterology, Endoscopy and Pancreaticobiliary Program (PBP)
Texas Children's Hospital
Baylor College of Medicine

DOUGLAS FISHMAN

Recent Publications

Thakkar K, Gilger MA, McOmber M, Shub M, Tsou M and Fishman DS. Quality Indicators for Pediatric Colonoscopy: Results from a Multi-Center Consortium. *Gastrointest Endosc.* 2015.

Rajjman I, Tarnasky PR, Patel S, Fishman DS, Surapaneni SN, Rosenkranz L, Talreja JP, Nguyen D, Gaidhane M and Kahaleh M. *Endosc Ultrasound.* 2015; 4(3): 213-8.

Schwarzenberg SJ, Bellin M, Husain SZ, Ahuja M, Barth B, Davis H, Durie PR, Fishman DS, Freedman SD, Garipey CE, Giefer MJ, Gonska T, Hewman M, Himes R, Kumar S, Morinville VD, Lowe ME, Nuehring NE, Ooi CY, Pohl JF, Troendle D, Werlin SL, Wilchanski M, Yen E, Uc A. Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden. *J Pediatr.* 2015; 166(4): 890-6.

Lerner DG, Li BU, Mamula P, Fishman DS, Kramer R, Goh VL, El-Chammas K, Pentiuik SP, Rothbaum R, Gurrum B, Rahhal RM, Goday PS, Vitola B. *J Pediatr Gastroenterol Nutr.* 2014 58(1): 27-33.

Harpavat S, Rajjman I, Hernandez JA and Fishman DS. Single-center experience of choledochoscopy in pediatric patients. *Gastrointest Endosc* 2012; 76(3): 685-8.

Mehta S, Lopez ME, Chumpitazi BP, Mazziotti MV, Brandt ML and Fishman DS. Clinical characteristics and risk factor for symptomatic pediatric gallbladder disease. *Pediatrics* 2012; 129(1): e82-8.

The Fishman research group focuses on the characterization of pediatric pancreaticobiliary disease in children as well as the study of pediatric endoscopic practice.

INSPPIRE International Multi-center Pancreatitis Registry

Baylor College of Medicine and Texas Children's Hospital were charter members of INSPPIRE in 2009. INSPPIRE: International Study Group of Pediatric Pancreatitis: In search for a cure). Our immediate goal is to develop a database of children with ARP and CP and to understand the epidemiology, etiologies, natural history and outcome in a well-phenotyped cohort of children with ARP and CP. We continue to develop an international multi-center consortium to prospectively study pediatric ARP and CP and determine the feasibility of long-term studies. We plan to determine the epidemiology and potential etiologic factors of ARP and CP in children. Drs. Fishman and Himes lead the local group under the leadership of Dr. Aliye UC at the University of Iowa. Our team also collaborates with Dr. William Fisher in the Elkins Pancreas Center, studying the relationship of diabetes and chronic pancreatitis to pancreatic cancer.

PEDS-CORI Endoscopy

Since 1999, Texas Children's has been the leader of PEDS-CORI, (Clinical Outcomes Research Initiative (PEDS-CORI) using a structured, computerized endoscopic reporting system to identify and monitor quality indicators for pediatric endoscopy. We are currently adding new sites with a goal of 14 active PEDS-CORI sites to include more than 100 pediatric gastroenterology providers. This is the most comprehensive pediatric endoscopy database in North America. PEDS-CORI has reported numerous findings related to various diseases in pediatric endoscopy and colonoscopy. We recently reported our findings in quality pediatric colonoscopy and aim to further delineate factors to improve quality. We seek to establish additional parameters that will serve as a tool for educators, clinicians and researchers in pediatric endoscopy.

PEDI (Pediatric ERCP Database Initiative) and Choledocholithiasis Research

Along with Dr. David Troendle at UTSW, we are a collaborator in the Pediatric ERCP Database, charged with evaluating and reporting ERCP quality for pediatric patients. This is a REDCAP based database using patient and physician reported information from biliary and pancreatic endoscopic procedures. A sub-group of the project is centered at Texas Children's seeking to identify appropriate testing algorithms for patients with possible choledocholithiasis (common bile duct stones) being evaluated for ERCP.

Email: douglas.fishman@bcm.edu



SANJIV HARPAVAT

Developmental Etiology and Clinical Studies of Biliary Atresia

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition

Recent Publications

Harpavat S, Finegold MJ, Karpen SJ. Biliary atresia patients have elevated direct/conjugated bilirubin levels shortly after birth. *Pediatrics* 2011, 128:e1428-33.

Tessier ME, Harpavat S, Shepherd RW, Hiremath GS, Brandt ML, Fisher A, Goss JA. Beyond the Pediatric end-stage liver disease system: solutions for infants with biliary atresia requiring liver transplant. *World J Gastroenterol* 2014 20(32): 11062-8.

Harpavat S, Devaraj S, Finegold MJ. An infant with persistent jaundice and a normal newborn direct bilirubin measurement. *Clin Chem* 2015 61(2): 330-3.

Harpavat S, Ramraj R, Finegold MJ, Brandt ML, Hertel PM, Fallon SC, Shepherd RW, Shneider BL. Newborn Direct/Conjugated Bilirubin Measurements As A Potential Screen for Biliary Atresia. *J Pediatr Gastroenterol Nutr* 2015 Dec 28 [Epub ahead of print].

Biliary atresia, the world's most common indication for pediatric liver transplant, is a poorly understood disease. One commonly held notion is that BA is acquired some time after birth. Two findings support this explanation: (a) infants often appear healthy at birth, and (b) BA does not follow a genetic pattern (discordant in twins, does not run in families). However, the observation that BA follows the same time course without exception, only affecting very young infants, encouraged us to question the acquired explanation.

To test exactly when BA starts, we asked a simple question: What are the direct/conjugated bilirubin concentrations for newborns later diagnosed with BA? We reasoned that if they were normal, then infants do not have disease at birth and instead acquire it a later time point. Alternatively, if they were elevated, then infants have disease at birth contrary to current explanations. To answer our question, we called the birth hospitals for infants with BA cared for at our institution. To our surprise, every infant with newborn measurements had elevated concentrations, which continued to rise with time. These results suggest infants are born with BA, and raise the possibility that BA should be considered a developmental disease.

Our current work builds on the initial observations, and follows two lines of research:

Validating a newborn screening system for BA based on direct/conjugated bilirubin measurements. Infants with BA have better outcomes when identified and treated earlier. Unfortunately, in the United States, the BA diagnosis is often delayed. To address this issue, we have initiated a prospective, multi-center screening study to determine whether newborn direct/conjugated bilirubin measurements can effectively identify infants with BA. In addition, we are analyzing the screen's cost-effectiveness, and assaying different ways to measure conjugated bilirubin concentrations from the state newborn screening blood spot cards.

Exploring intrahepatic and extrahepatic bile duct development, to understand what causes BA. In these experiments, we examine bile ducts at two levels. First, human liver tissue from BA patients is probed using immunohistochemistry, to identify which signaling pathways are perturbed in disease. Second, mouse models are used to recapitulate a BA-like phenotype. For these experiments, we use lineage tracing and condition knock-out technology.

harpavat@bcm.edu



PAULA M. HERTEL

Infantile Disorders of Biliary Function: Closing Current Knowledge Gaps

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition

Recent Publications

Zhou S, Hertel PM, et al. Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. *Hepatology*. 2015 ; 62:1914-6.

Kamath BM, Chen Z, Romero R, Fredericks EM, Alonso EM, Arnon R, Heubi J, Hertel PM, Karpen SJ, Loomes KM, Murray KF, Rosenthal P, Schwarz KB, Subbarao G, Teckman JH, Turmelle YP, Wang KS, Sherker AH, Sokol RJ, Magee JC; Childhood Liver Disease Research Network (ChiLDRn). Quality of Life and Its Determinants in a Multi-center Cohort of Children with Alagille Syndrome. *J Pediatr*. 2015; 167(2):390-6

Teckman JH, Rosenthal P, Abel R, Bass LM, Michail S, Murray KF, Rudnick DA, Thomas DW, Spino C, Arnon R, Hertel PM, et al. Baseline analysis of a young alpha-1-AT deficiency liver disease cohort reveals frequent portal hypertension. *J Pediatr Gastroenterol Nutr*. 2015; 61:94-101.

Venkat VL, Shneider BL, Magee LJ, Turmelle Y, Arnon R, Bezerra JA, Hertel PM, et al. Total serum bilirubin predicts fat-soluble vitamin deficiency better than serum bile acids in infants with biliary atresia. *Childhood Liver Disease Research and Education Network. J Pediatr Gastroenterol Nutr* 59(6):702-7 (2014).

Bezerra JA, Spino C, Magee JC, Shneider BL, Rosenthal P, Wang KS, Erlichman J, Haber B, Hertel PM, et al. Use of corticosteroids after hepatopuertoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial. *JAMA* 2014; 311 (17):1750-9.

Disorders of bile flow (cholestatic liver diseases) that present during infancy and childhood are diverse and, in many respects, still poorly understood. Collectively, these diseases are not uncommon, but individually, they are rare. Biliary atresia, the most common indication for liver transplantation in children, occurs in only approximately 1:10,000 live births. Many other infantile cholestatic liver diagnoses are even less common.

Often, the etiology of cholestasis during infancy is multifactorial. Bile flow may be impaired by numerous factors such as infection, hemolysis, and parenteral nutrition, and bile flow in the immature liver is particularly vulnerable to becoming impaired following one or more of these insults. Genetic factors may also contribute to vulnerability to cholestasis; variants in genes such as those implicated in alpha-1-antitrypsin deficiency and progressive familial intrahepatic cholestasis are known to play roles in cholestasis in early life. The cause(s) of cholestasis may remain undetermined in many young patients, however.

Texas Children's Hospital and Baylor College of Medicine Division of Pediatrics Gastroenterology and Nutrition participates in an NIH-funded, multi-center consortium known as "ChiLDRn" (Childhood Liver Disease Research Network – children-network.org). The Network consists of fourteen clinical sites in the United States and Canada, each of which enrolls children with cholestatic liver diseases in protocols that include four long-term observational studies as well as therapeutic drug trials. The strength of the Network lies in its prospective, longitudinal (up to 10 years) study of children with liver diseases, as well as its ability to capture substantial numbers of study subjects diagnosed with rare diseases by virtue of involvement of multiple top pediatric tertiary care hospitals.

Dr. Hertel is responsible for the conduct of the ChiLDRn Network observational protocols at the Texas Children's Hospital site, is Chair of the Idiopathic Neonatal Hepatitis working group, and is an active participant in the PFIC (progressive familial intrahepatic cholestasis) and Biliary Atresia Genomics and Pathophysiology workgroups. A wonderful opportunity exists to access the Network's data and tissue repository by submission (and approval) of ancillary proposals – please contact Dr. Hertel or one of our other ChiLDRn site Co-Investigators for more information. Dr. Hertel would be pleased direct those interested to a contact with compatible interests.

Email: phertel@bcm.edu



FAROOK JAHOUR

Intermediary Metabolism in Health and Disease

Professor
Department of Pediatrics
Children's Nutrition Research Center

Recent Publications

Dwarkanath P, Hsu JW, Tang GJ, Anand P, Thomas T, Thomas A, Sheela CN, Kurpad AV, Jahoor F. Energy and Protein Supplementation Does Not Affect Protein and Amino Acid Kinetics or Pregnancy Outcomes in Underweight Indian Women. *J Nutr*. 2016 Feb;146(2):218-26.

Green CO, Badaloo AV, Hsu JW, Taylor-Bryan C, Reid M, Forrester T, Jahoor F. Effects of randomized supplementation of methionine or alanine on cysteine and glutathione production during the early phase of treatment of children with edematous malnutrition. *Am J Clin Nutr*. 2014 ;99(5):1052-8.

Hsu JW, Jahoor F, Butte NF, Heird WC. Rate of phenylalanine hydroxylation in healthy school-aged children. *Pediatr Res*. 69:341-6, 2011.

Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balasubramanyam A, Jahoor F. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. *Diabetes Care*. 34:162-7, 2011.

Jahoor F, Badaloo A, Reid M, Forrester T. Protein metabolism in severe childhood malnutrition. *Ann Trop Paediatr*. 28(2):87-101, 2008. Review.

Jahoor F, Badaloo A, Villalpando S, Reid M, and Forrester T. Arginine Flux and Intravascular Nitric Oxide Synthesis in Severe Childhood Undernutrition. *Am J Clin Nutr*, 86: 1024-31, 2007.

Jahoor F, Badaloo A, Reid M and Forrester T. Sulfur amino acid metabolism in children with severe childhood undernutrition: Cysteine kinetics. *Am J Clin Nutr*, 84: 1400-5, 2006.

The primary research interests of my lab focus on the modifications of macronutrient metabolism in conditions such as diabetes mellitus, overweight and obesity, severe protein-energy malnutrition, acute and chronic infections, sepsis, pregnancy and ageing and how these modifications impact other aspects of physiological function and aspects of host defense, in particular, the capacity to synthesize the antioxidant glutathione and the acute phase proteins. The goal is to determine how these changes in turn precipitate other pathologies, and to use the metabolic information obtained to design novel therapeutic strategies to counter these derangements. To achieve these goals current research efforts utilize stable isotope tracer methodologies and a combination of animal models and patient populations. Ongoing research centers on:

- The alterations of protein and glucose metabolism in sepsis.
- Lipid and glucose metabolism in HIV infected individuals with lipodystrophy and insulin resistance.
- Sulfur amino acid metabolism and glutathione homeostasis in the pathogenesis of Kwashiorkor.
- Aromatic amino acid metabolism in children with severe childhood undernutrition.
- Determination of how maternal obesity and undernutrition alter the metabolic/ physiologic adaptations necessary for a successful pregnancy.
- Role of nitric oxide synthesis in the hypotension of sepsis.

Email: fjahoor@bcm.edu



Epigenomic and Microbiomic Aspects of Inflammatory Bowel Disease

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Children's Nutrition Research Center

RICHARD KELLERMAYER

Recent Publications

Fofanova TY, Petrosino JF, Kellermayer R. Microbiome-Epigenome Interactions and the Environmental Origins of Inflammatory Bowel Diseases. *J Pediatr Gastroenterol Nutr.* 2016;62:208-19.

Nagy-Szakal D., Mir SAV., Harris RA., Dowd SE., Yamada T., Laccorazza D., Tatevian N., Smith CW., de Zoeten EF., Klein J., Kellermayer R. Loss of omega-6 fatty acid induced pediatric obesity protects against acute murine colitis. *FASEB J.* 2015 Aug;29(8):3151-9.

Kellermayer, R., Nagy-Szakal, D., Harris, A.R., Luna, R. A., Pitashny, M., Schady, D., Mir, S.A.V, Lopez, M.E., Gilger, M. A., Belmont, J., Hollister, E. B., Versalovic, J. Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. *Am J Gastroenterol.* 2015;110(4):604-6

Harris RA, Nagy-Szakal D, Mir SA, Frank E, Szigeti R, Kaplan JL, Bronsky J, Opekun A, Ferry GD, Winter H, Kellermayer R. DNA methylation-associated colonic mucosal immune and defense responses in treatment-naïve pediatric ulcerative colitis. *Epigenetics.* 2014;9(8):1131-7.

Mir SA, Nagy-Szakal D, Smith EO, Gilger MA, Kellermayer R. Duration of disease may predict response to infliximab in pediatric ulcerative colitis. *J Clin Gastroenterol.* 2014;48:248-52.

Our laboratory approaches inflammatory bowel diseases from the perspective of the developmental origins hypothesis. This hypothesis postulates that at various stages of development critical changes in organismic structures can occur as a result of environmental influences. Such critical changes are then maintained throughout life and influence our susceptibility to common disorders, such as inflammatory bowel diseases (IBD), for example. IBD develop on the basis of an exaggerated immune response against the enteric microflora that is transmitted by the intestinal epithelium. One molecular process that has been recognized to potentially play a major role in the developmental origins of human diseases is DNA methylation. DNA methylation is the most stable epigenetic process and can respond dynamically to microbiota changes in the intestinal mucosa. Therefore, epigenetic and microbime alterations may be intimately related in the mammalian gut. We are studying how nutritional and genetic changes can modify the intercalating network of the mucosal epigenome and microbiome in association with mammalian colitis. Our recent clinical and basic research focus is complex (fecal microbiota transplantation) and select bacteriotherapy to treat murine models of colitis and IBD. These studies should provide the basis for novel diagnostic, preventative and therapeutic measures for IBD.

Email: kellerma@bcm.edu



BRENDAN HI LEE

Biochemical Genetics of the Urea Cycle and Nitric Oxide Synthesis

Professor
Robert and Janice McNair Endowed Chair and Professor
Chairman, Department of Molecular and Human Genetics
Baylor College of Medicine

Recent Publications

M.H. Premkumar, G. Sule, S.C. Nagamani, S. Chakkalakal, A. Nor-din, R. Zhechao, M. Jain, T. Bertin, J. Zhang, D. Schady, N.S. Bryan, P.M. Campeau, A. Erez, and B. Lee. Argininosuccinate lyase in enterocytes protects from development of necrotizing enterocolitis. *American Journal of Physiology Gastrointestinal and Liver Physiology*, 307:G347-54 (2014).

G.A. Diaz, L.S. Krivitzky, M. Mokhtarani, W. Rhead, J. Bartley, A. Feigenbaum, N. Longo, W. Berquist, S.A. Berry, R. Gallagher, U. Lichter-Konecki, D. Bartholomew, C.O. Harding, G. Vockley, S.A. Bart, M.S. Korson, D. Kronn, R. Zori, J.L. Merritt II, S. Sreenath-Nagamani, J. Mauney, C. LeMons, K. Dickinson, T.L. Moors, D.F. Coakley, B.F. Scharschmidt, and B. Lee. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. *Hepatology*, 57:2171-9 (2013).

W. Smith, G.A. Diaz, U. Lichter-Konecki, S.A. Berry, C.O. Harding, S.E. McCandless, C. Lemons, J. Mauney, K. Dickinson, D.F. Coakley, T. Moors, M. Mokhtarani, B.F. Scharschmidt, and B. Lee. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: Comparison of sodium phenylbutyrate and glycerol phenylbutyrate. *Journal of Pediatrics*, 162:1228-1234 (2013).

Nagamani, O.A. Shchelochkov, M.A. Mullins, S. Carter, B.C. Lanpher, Q. Sun, S. Kleppe, A. Erez, E.O. Smith, J. Marini, Members of the Urea Cycle Disorders Consortium, and B. Lee. A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. *Molecular Genetics and Metabolism*, 107:315-21 (2012).

The overall mission of my research program is to translate the study of structural birth defects and inborn errors of metabolism into a basic understanding of development, disease, and novel therapeutic approaches. My research program ranges from study of basic developmental mechanisms to interventional clinical trials. One longstanding area has been the genetic study of biochemical genetic disorders (specifically urea cycle disorders) as models of complex disease (those involving nitric oxide dysregulation). This area has encompassed generation of mouse models of urea cycle disorders (UCDs), stable isotopic metabolic studies in patients with UCDs, longitudinal observational studies, and both investigator-initiated and industry-sponsored interventional trials. In parallel, I have also attempted to develop cell, protein, and viral gene therapy for these conditions (urea cycle disorders, hyperbilirubinemia, hemophilia), in addition to studying the immune response to these therapies.

My clinical research program began with stable isotopic measurements in humans and UCD patients to better diagnose patients with disorders of urea cycle flux and to evaluate the differential bioavailability of different sources of nitrogen (enteral vs. parenteral) to the urea cycle. These human studies have evolved to measure nitric oxide flux in patients with UCDs and specifically with arginase deficiency and argininosuccinic aciduria. These studies have led us to more broadly ask how enzymes of the urea cycle including those that synthesize and degrade arginine, i.e., argininosuccinate lyase and arginase, respectively, regulate systemic nitric oxide synthesis in a variety of human diseases including liver fibrosis and necrotizing enterocolitis.

Interventional studies include the Phase II and III studies of a novel ammonia scavengers in UCD patients and phenylbutyrate/arginine treatment in patients with argininosuccinic aciduria. Currently, I direct the Baylor College of Medicine/Texas Children's Hospital site of the Urea Cycle Disorders Rare Disease Clinical Research Network. As part of this site, we perform both investigator initiated and industry sponsored studies on treatment of UCDs.

Email: blee@bcm.tmc.edu



DANIEL H. LEUNG

Viral Hepatitis and Cystic Fibrosis Liver Disease

Associate Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Director of Viral Hepatitis Clinic
Texas Children's Hospital

Recent Publications

Leung, DH, Ye, Wen, Molleston, JP, Weymann, A, Ling, S, Paranjape, S, Romero, R, Schwarzenberg, Doo, E, Seigel, M, Krishnamurthy, R, Harned, R, Karmazyn, B, Magee, J, Narkewicz, M. Baseline ultrasound and clinical correlates in children with Cystic Fibrosis (CF). *Journal of Pediatrics*. 2015;167(4):862-868.

Amin, M, Harpavat, S, Leung, DH. Drug Induced Liver Injury in Children. *Current Opinion in Pediatrics*. 2015;27(5):625-33.

Leung, DH, Minard, C, Guffey, D, Ramm, LE, Lewindon, P, Clouston, A, Shepherd R, Ramm, GA. Aspartate Aminotransferase to Platelet Ratio and Fibrosis-4 as Biomarkers in Biopsy Validated Pediatric Cystic Fibrosis Liver Disease. *Hepatology*. 2015;62(5):1576-83.

Shneider B, de Ville de Goyet J, Leung D, Srivastava A, Squires R, Sarin S, de Franchis R, Mazariegos G. Primary prophylaxis of variceal bleeding in children and the role of the mesorex bypass - Summary of the Baveno VI pediatric satellite symposium. *Hepatology*. 2016;63:1368-1380

Xue, M, Glenn, JS, and Leung, DH. Invited Review: Hepatitis D (HDV) in children. *J Pediatr Gastroenterol Nutr*. 2015 May 20.

Leung, DH, Ton-That, M, Economides, E, Healy, CM. High prevalence of Hepatitis B non-immunity in vaccinated pediatric liver transplant recipients. *American Journal of Transplantation*. 2015;15:535-40.

Khaderi, SA, Shepherd, RW, Goss, JA, Leung, DH. Hepatitis C in the Pediatric Population: Transmission, Natural History, Treatment and Liver Transplantation. *World Journal of Gastroenterology*. 2014; 28; 20 :11281-11286.

Dr. Leung oversees the Viral Hepatitis Clinic at Texas Children's Hospital which features a robust clinical program, managing and counseling nearly 200 established patients with hepatitis B and C. 7 clinical trials in the treatment of hepatitis are conducted from the clinic with new protocols studying the safety and efficacy of direct acting antivirals for children infected with HCV. Other research protocols within the hepatitis clinic include the study of shearwave elastography, serum biomarkers, and simple biomarkers.

Dr. Leung's research spans disciplines within hepatology and gastroenterology such as cystic fibrosis (CF), the intestinal microbiome, and nutritional outcomes. Dr. Leung currently has funding from the NIH, CF Foundation, CF Therapeutics Development Network, and Texas Children's Hospital Pediatric Pilot Award. His efforts as site PI of the NIH funded CF Liver Disease Network has led to BCM being recognized as the largest enrolling site in the country. For the last 5 years, Dr. Leung has served as Lead Co-Principal Investigator of the Cystic Fibrosis Foundation (CFF) funded Multi-center Infant Nutrition Observational Study in Children identified by Newborn screen (BONUS) study in tandem with Dr. Drucy Borowitz, a matriarch in the field of pediatric cystic fibrosis. His unique skill set in gastrointestinal and hepatology care within cystic fibrosis was recognized by the CFF and he was awarded a Developing Innovative Gastroenterology Specialty Training (DIGEST) Program grant through 2017 to be further mentored by pioneers within the CF GI and Liver field. He is currently a co-investigator for a NIH R01 funded project in the CF Infant microbiome and sits on the Cystic Fibrosis Foundation and Therapeutic Development Network Clinical Research Award and Grants Committee, which has awarded more than \$2 million in annual grant funding.

Email: dhleung@bcm.edu



Regulation of Gastric Barrier Function; Gastric Homeostasis in Health & Disease

Professor
Department of Integrative Biology and Pharmacology
University of Texas Medical School at Houston

LENARD LICHTENBERGER

Recent Publications

Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. *Am J Gastroenterol*. 106:272-7, 2011.

Zhou Y, Plowman SJ, Lichtenberger LM, Hancock JF. The anti-inflammatory drug indomethacin alters nanoclustering in synthetic and cell plasma membranes. *J Biol Chem*. 5;285:35188-95, 2010.

Zhou Y, Dial EJ, Doyen R, Lichtenberger LM. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. *Am J Physiol* 298:G722-31, 2010.

Zhou Y, Hancock JF, Lichtenberger LM. The nonsteroidal anti-inflammatory drug indomethacin induces heterogeneity in lipid membranes: potential implication for its diverse biological action. *PLoS One* 5:e8811, 2010.

Zhou Y, Doyen R, Lichtenberger LM. The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. *Biochim Biophys Acta* 1788:507-513, 2009.

Lichtenberger LM, Romero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when selective cyclooxygenase-2 inhibitor (coxib) is used in combination with aspirin. *Brit J Pharmacol* 150:913-919, 2007.

Darling RL, Romero JJ, Dial EJ, Akunda JK, Langenbach R, Lichtenberger LM. Effects of aspirin on gastric mucosal integrity, hydrophobicity and prostaglandins in cyclooxygenase knockout mice. *Gastroenterology* 127: 94-104, 2004.

The major focus of my lab is to study the barrier properties of the upper GI tract in health and disease, and specifically the role of phospholipids in the genesis of a surface hydrophobic barrier to acid and other luminal necrotizing factors. The two areas of research that have relevance to pediatric gastroenterology, is to study the importance of this barrier in the protection of the developing gut, and in specific diseases associated with mucosal ulceration (e.g. necrotizing enterocolitis, NSAID-induced peptic ulceration, and multiple organ failure). We are currently studying the contribution of surface phospholipids in pathogenesis of NSAID-induced GI ulceration, and intestinal injury/inflammation associated with traumatic injury, that may be an important trigger in the development of multiple-organ failure. This research may have clear relevance not only in increasing our understanding of pathogenesis of digestive diseases, but in providing new therapeutic approaches to attenuate GI injury. This is underscored by the fact that we have developed a phospholipid-associated NSAID (ibuprofen-PC) that is currently in Phase II clinical trial. Trainees in the future, as in the past, will have their own independent research project that bridges the interest of the mentor's lab and goals of the pediatric GI training grant. The trainees will be expected to present their results before the mentor's weekly lab meeting and annually at both the local seminar series of the pediatric GI program and at a national pediatric/GI meeting.

Email: Lenard.M.Lichtenberger@uth.tmc.edu



TAMIR MILOH

Clinical Outcomes in Pediatric Liver Transplantation

Associate Professor
Director of Pediatric Liver Center
Baylor College of Medicine

Recent Publications

Miloh T, Arnon R, Shneider B.L, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterology Hepatology 2009 Feb; 7(2):239-45.

Miloh T, Annunziato R, Arnon R, Warshaw J, Parkar S, Suchy F. J, Iyer K, Kerkar N. Text messaging improves adherence and reduces rejection in pediatric liver transplant recipients. Pediatrics, Nov;124(5):e844-50.

Miloh T, Kerkar N. Sclerosing Cholangitis- Pediatric perspective. Current Gastroenterology Reports 2010 Jun;12(3):195-202.
Shemesh E, Annunziato R, Miloh T, Arnon R, Kerkar N. Adherence to medical recommendations and transition to adult services in pediatric transplant recipients. Curr Opin Organ Transplant 2010 Jun;15(3):288-92.

Miloh T, Kerkar N, Parkar S, Annunziato R, Mendez C, Arnon R, Iyer K. Improved outcomes in pediatric liver transplantation for acute liver failure, Pediatric Transplant. 2010 Nov;14(7):863-9.


Annunziato R, Hogan B, Barton C, Miloh T, Arnon R, Iyer K, Kerkar N. A translational and systemic approach to transferring liver transplant recipients from pediatric to adult oriented care settings. Pediatric Transplant. 2010 Nov;14(7):823-923.

Arnon R, Annunziato R, Miloh T, Sogawa H, Nostrand K. V, Suchy F, Kerkar N. Liver transplantation in children weighing 5 kg or less: Analysis of the UNOS database. Pediatr Transplant. 2011 Sep;15(6):650-8.

Wadera S, Magid MS, McOmber M, Carpentieri D, Miloh T. Atypical presentation of Wilson disease. Semin Liver Dis. 2011 Aug; 31(3):319-26.

Texas Children's Hospital has a comprehensive pediatric hepatology program and has performed nearly 500 pediatric liver transplants in children and is one of the largest programs in the country. The multidisciplinary team is dedicated to multicenter and Texas Children's led studies to improve outcomes in children after liver transplants. We are one of the few centers in the US that offers extracorporeal liver support such as MARS and TP. Texas Children's Liver Center is one of the few pediatric liver centers in the country with a fully-equipped, state-of-the-art research laboratory dedicated to basic and clinical research aimed at improving the care and outcomes for children with liver disease. We are among only a handful of centers in the nation and the only one in Texas that participate in multiple National Institute of Health-sponsored protocols including CHILDREN, NASH CRN, CF and iWITH. We are members of SPLIT and collaborate on dozens of multicenter trials. We participate in novel pharmaceutical trials, such treatments for chronic hepatitis B and C, itching in chronic liver disease. TCH is home to one of the busiest biliary atresia, hepatoblastoma, metabolic/genetic liver disease and non alcoholic fatty liver disease clinics in the nation. Specific areas of interest: adherence and transition of care, primary sclerosing cholangitis, autoimmune hepatitis and Wilson disease.

Email: tamiloh@texaschildrens.org



Metabolic Regulation by Nuclear Receptors

Professor
Department of Molecular and Cellular Biology
Baylor College of Medicine

DAVID D. MOORE

Recent Publications

Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim MS, Kim KH, Shneider BL, Picarsic JL, Jacobson TA, Zhang J, He W, Liu P, Knisely AS, Finegold MJ, Muzny DM, Boerwinkle E, Lupski JR, Plon SE, Gibbs RA, Eng CM, Yang Y, Washington GC, Porteus MH, Berquist WE, Kambham N, Singh RJ, Xia F, Enns GM, Moore DD. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. *Nat Commun*. 2016;7:10713.

LRH-1 is a critical determinant of methyl-pool metabolism. Wagner M, Choi S, Panzitt K, Mamrosh JL, Man Lee J, Zaufel A, Xiao R, Wooton-Kee R, Ståhlman M, Newgard CB, Borén J, Moore DD. *Hepatology*. 2016 Jan;63(1):95-106.

Elevated copper impairs hepatic nuclear receptor function in Wilson's disease. Wooton-Kee CR, Jain AK, Wagner M, Grusak MA, Finegold MJ, Lutsenko S, Moore DD. *J Clin Invest*. 2015 Sep;125(9):3449-60.

Activating CAR and β -catenin induces uncontrolled liver growth and tumorigenesis. Dong B, Lee JS, Park YY, Yang F, Xu G, Huang W, Finegold MJ, Moore DD. *Nat Commun*. 2015; 9:6:5944.

Nutrient-sensing nuclear receptors coordinate autophagy. Lee JM, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA, Moore DD. *Nature*. 2014;516:112-5.

Nuclear receptor LRH-1/NR5A2 is required and targetable for liver endoplasmic reticulum stress resolution. Mamrosh JL, Lee JM, Wagner M, Stambrook PJ, Whitby RJ, Sifers RN, Wu SP, Tsai MJ, Demayo FJ, Moore DD. *Elife*. 2014 Apr 15;3:e01694.

Nuclear Hormone Receptors Regulate Metabolism and Cancer

The 48 members of the nuclear hormone receptor superfamily function as ligand-dependent or, in some cases, ligand-independent transcription factors. The major goal of this laboratory is to understand the roles of the newer members of this superfamily, particularly their impact on metabolic and oncogenic pathways in the liver. One major focus is on CAR, which functions to regulate the response of the liver to xenobiotics, potentially toxic foreign compounds. Activation of CAR by specific xenobiotic stimuli, and also by toxic endogenous compounds such as bile acids and bilirubin, increases the liver's ability to metabolize and eliminate them. CAR-dependent responses are generally protective, but can be deleterious. Thus, chronic activation of CAR by non-genotoxic carcinogens results in liver tumors, due to direct effects of CAR on both hepatocyte proliferation and apoptosis. We are pursuing both the mechanism of this tumor promotion and therapeutic approaches that block it.

We are also studying the role of nuclear receptors in response to other stresses in the liver. We have found that PPARalpha, which is activated in the fasted state, can induce autophagy to promote nutrient availability. In the opposite direction, FXR is activated in the fed state, and blocks such nutrient recycling when it is not needed. More broadly, we are studying the role of FXR in managing energy balance in the resource rich fed state, and the role of PPARalpha in the resource poor fasted state. Overall, we will continue to use pharmacologic and mouse knockout approaches to explore the diverse metabolic and oncogenic functions of the nuclear hormone receptors.

Email: moore@bcm.edu



MARC RHOADS

Probiotic Mechanism of Action in GI Diseases

Professor
Division Head of Pediatric Gastroenterology
Fellowship Program Director
University of Texas Health Sciences Center at Houston

Recent Publications

Fatheree NY, Liu Y, Ferris M, Van Arsdall M, McMurtry V, Zozaya M, Cai C, Rahbar MH, Hessabi M, Vu T, Wong C, Min J, Tran DQ, Navarro F, Gleason W, Gonzalez S, Rhoads JM. Hypoallergenic formula with *Lactobacillus rhamnosus* GG for babies with colic: A pilot study of recruitment, retention, and fecal biomarkers. *World J Gastrointest Pathophysiol.* 2016;15;7:160-70.

Liu Y, Fatheree NY, Mangalat N, Rhoads JM. *Lactobacillus reuteri* strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NFkB signaling in the intestine. *Am J Physiol.* 2012; 15;302:G608-17.

Liu Y, Fatheree NY, Dingle BM, Tran DQ, and Rhoads JM. *Lactobacillus reuteri* DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. *PLoS One.* 2013;8 (2):e56547.

Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human derived probiotic *Lactobacillus reuteri* strains differentially reduce intestinal inflammation. *Am J Physiol.* 2010; 299(5):G1087-96.

Liu Y, Zhu L, Liu X, Pacheco S and Rhoads JM. Changes in intestinal Toll-like receptors and cytokines precede histological injury in a rat model of necrotizing enterocolitis. *Am J Physiol;* 297:442-450, 2009.

The Pediatric Gastroenterology Research Lab was established in 2007. It is co-directed by Yuying Liu, Ph.D., Med., Assistant Professor, and by J. Marc Rhoads, MD., Professor and Division Head of Gastroenterology.

Since 2007, our basic research has been focusing on mechanisms of neonatal necrotizing enterocolitis (NEC) which is the leading cause of gastrointestinal morbidity in premature infants. We have found the critical roles of Toll-like receptor (TLR) and TLR-signaling regulators and mediators, as well as an imbalance of Foxp3+ regulatory T (Treg) and effector memory T (Tem) cell, which promote the development of NEC. In addition, we have been studying the effects of probiotic *Lactobacillus reuteri* (LR) strains on the development of NEC. Our studies showed the LR reduced the incidence and severity of NEC in animal models via modulation of TLR4 and NFkB signaling in the intestine. LR also causes redistribution to the Tcell subsets in the intestinal mucosa.

Recently, we observed the LR markedly prolong the survival of Foxp3-deficient scurfy (sf) mice, which may provide evidence for using probiotic LR to treat patients with IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) or patients with other autoimmune diseases. We are investigating changes in the microbiota produced by this disease and severe changes in the fecal and plasma metabolic profile. The changes seen are markedly modified by oral *L. reuteri* treatment.

Drs. Liu & Rhoads also are actively investigating the mechanisms by which LR regulates intestinal inflammation *in vitro* and animal models. The project is designed to investigate how mucosa dendritic cells and Tcells (TH1, TH17, and Tregs) respond to probiotics, and which cells control gastrointestinal inflammation of the newborn. Moreover, we will show if LR treatment increases fecal microbial richness and diversity and alters their metabolic products, in order to understand local systemic beneficial effects. Ultimately, we hope to provide novel insight into the mechanisms of how probiotics regulate neonatal intestinal inflammation.

Our clinical research on colic, which we showed to be an inflammatory condition in babies who cry excessively. We were first to demonstrate elevated fecal calprotectin in this population, indicating that there is an intestinal inflammation in these babies. We are analyzing the microbiota and fecal calprotectin in babies treated with *L. reuteri* versus placebo in a "road to discovery" trial.

Email: j.marc.rhoads@uth.tcm.edu



Emerging Concepts in Gut Microbiome - Enteric Nervous System Function and Disease

Associate Professor
Texas Children's Microbiome Center
Department Pathology and Immunology
Baylor College of Medicine

TOR SAVIDGE

Recent Publications

Savidge TC. Epigenetic Regulation of Enteric Neurotransmission by Gut Bacteria. *Front Cell Neurosci.* 2016; 8:9:503.

MacEachern SJ, Patel BA, Keenan CM, Dickey M, Chapman K, Savidge TC, Beck PL, MacNaughton WK, Sharkey KA. Inhibiting Inducible Nitric Oxide Synthase in Enteric Glia Restores Electrogenic Ion Transport in Mice With Colitis. *Gastroenterology.* 2015;149:445-55.

Sharkey KA, Savidge TC. Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. *Auton Neurosci.* 2014;181:94-106

Oezguen N, Power TD, Urvil P, Feng H, Pothoulakis C, Stamler JS, Braun W, Savidge TC. Clostridial toxins: sensing a target in a hostile gut environment. *Gut Microbes.* 2012; 3:35-41.

Savidge TC, Urvil P, Oezguen N, Ali K, Choudhury A, Acharya V, Pinchuk I, Torres AG, English RD, Wiktorowicz JE, Loeffelholz M, Kumar R, Shi L, Herman B, Hausladen A, Feng H, Stamler JS, Pothoulakis C. Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. *Nat Med.* 2011;17(9):1136-41.

Savidge TC, Newman P, Pothoulakis C, Ruhl A, Neunlist M, Bourreille A, Hurst R, Sofroniew MV. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. *Gastroenterology.* 2007;132:1344-58.

Dr. Savidge's laboratory is focused on several emerging research concepts, centering on gut microbiota interactions with the enteric nervous system in the induction of intestinal disease. As principal investigator of an independently NIH funded GI research laboratory focusing on neuroimmune-microbe interactions, research efforts are focused on microbial metabolites and neurotransmitter signals that regulate *Clostridium difficile* pathogenesis. Recent investigative efforts include the discovery of novel small molecule activators and inhibitors of bacterial toxins, and mechanisms of neurotoxin action (*Nature Medicine* (2011) 17:1136-41). Dr. Savidge was one of the first to report *C. difficile* toxin B as the major virulence factor in human intestine and research is now focused on understanding how these toxins interact with the host as a way of identifying new approaches to inhibit the disease (*Gastroenterology* (2003) 125:413-420). Identification of novel small molecule functions in patient specimens has been facilitated by microbiome and metabolomics studies in the Texas Children's Microbiome Center. Recently, these studies led to the new discovery that protein-ligand interactions with bulk water can influence binding affinity and enzyme catalysis (*Science* (2015) 349:936-938).

Another emerging research concept that Dr. Savidge has actively pioneered is the involvement of the enteric nervous system in intestinal inflammation, notably a previously unappreciated protective role for glial cells in the gut. Enteric glia represent an extensive but poorly characterized cell lineage in the enteric nervous system. Although previously regarded as passive support cells for enteric neurons, there is now an emerging recognition that enteric glia directly regulate enteric nervous system function and mucosal homeostasis. Dr. Savidge's research played a central role in establishing these novel glial cell concepts, and was the first to demonstrate fulminant intestinal inflammation resulting from loss of glia in the intestine (*Cell* (1998) 93:189-201 & *PNAS* (2001) 98:13306-13311). Since then, he has been actively investigating the functional analogy between glial regulation of barrier function in the gut and blood brain barrier, identifying nitric oxide derivatives known as S-nitrosothiols as glial-derived protective molecules in the intestine (*Gastroenterology* (2007) 132:1344-1358). To study the biology of these nitric oxide derivatives, new systems biology tools have been developed in the Texas Children's Microbiome Center and are being applied to identify new microbiota S-nitrosothiol signals.

Email: Tor.Savidge@bcm.edu



BENJAMIN SHNEIDER

Basic and Translational Research in Bile Acid Homeostasis and Disease

Professor
Chief, Section Gastroenterology, Hepatology and Nutrition
George Peterkin Endowed Chair
Department of Pediatrics
Baylor College of Medicine

Recent Publications

Total Serum Bilirubin within 3 Months of Hepatoportoenterostomy Predicts Short-Term Outcomes in Biliary Atresia. Shneider BL, Magee JC, Karpen SJ, Rand EB, Narkewicz MR, Bass LM, Schwarz K, Whittington PF, Bezerra JA, Kerkar N, Haber B, Rosenthal P, Turmelle YP, Molleston JP, Romero R, Squires RH, Arnon R, Sherker AH, Moore J, Ye W, Sokol RJ. *J Pediatr*. 2016 Mar;170:211-217

Solder D, Ghosh A, Chen F, Shneider B. "A single element in the 3'UTR of the Apical Sodium-Dependent Bile Acid Transporter controls both stabilization and destabilization of mRNA." *Biochemical Journal*. 2014 September 15;462(3):547-53.

Teckman JH, Rosenthal P, Abel R, Bass LM, Michail S, Murray KF, Rudnick DA, Thomas DW, Spino C, Arnon R, Hertel PM, Heubi J, Kamath BM, Molleston JP, Romero R, Shneider BL, Sherker AH, Sokol RJ. "Baseline Analysis of a Young Alpha-1-AT Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension." *J Pediatr Gastroenterol Nutr*. 2015

Jericho HS, Kaur E, Boverhof R, Knisely A, Shneider BL, Verkade HJ, Whittington PF. "Bile acid pool dynamics in progressive familial intrahepatic cholestasis with partial external bile diversion." *J Pediatr Gastroenterol Nutr*. 2015 March;60(3):368-74.

Morris AL, Bukauskas K, Sada RE, Shneider BL. "Byler disease: early natural history." *J Pediatr Gastroenterol Nutr*. 2015 April;60(4):460-6.

Benjamin Shneider is a Pediatric Hepatologist with basic research expertise in intestinal gene regulation, bile acid transport and mechanisms of cholestasis. He is actively involved in clinical and translational investigations of liver diseases in children. Dr. Shneider's leadership goal is to leverage the wide-ranging clinical and research expertise of an exceptionally talented section to provide compassionate, state-of-the-art, discipline-leading and evidence-based care for children with all types of gastrointestinal, hepatic, pancreatic and nutritional disorders. Rapidly-paced advances in biomedical knowledge provide an unprecedented opportunity to simultaneously advance both clinical care and the science of medicine. As Chief of Pediatric Gastroenterology, Hepatology and Nutrition at Texas Children's Hospital and the Baylor College of Medicine, Dr. Shneider will encourage and lead expanding activities in both education and research in order to optimally capitalize on these rapidly paced biomedical advances.

Dr. Shneider's primary area of basic investigation focuses upon the complex molecular mechanisms involved in the regulation of intestinal bile acid transport. Intestinal reabsorption of bile acids, mediated by the apical sodium dependent bile acid transporter (ASBT = SLC10A2), plays a critical role as a pivotal control point for not only bile acid homeostasis through its effects on the enterohepatic circulation of bile acids, but also in regulating ileal and colonic metabolic signaling in response to bile acids. Dr. Shneider's laboratory has explored the regulated responses of ASBT to changes in bile acid homeostasis, signaling by growth factors and inflammatory cytokines and during normal ontogeny. Dr. Shneider is also actively involved in clinical investigation of various pediatric liver diseases (e.g. biliary atresia, familial cholestasis, acute liver failure and sclerosing cholangitis). He has been a principal investigator in the Childhood Liver Disease Research Network since its inception in 2002. Juxtaposition of his basic and clinical research expertise has led to novel translational inquiries into cholestatic liver disease, especially Byler's Disease. Dr. Shneider has consistently pursued advances in evidence-based approaches to the diagnosis and treatment of pediatric liver disorders with particular interest in issues related to chronic cholestasis, cirrhosis and portal hypertension.

Email: Benjamin.Shneider@bcm.edu



NOAH SHROYER

Mechanisms that Control Intestinal Development and Homeostasis and Human Enteroids

Associate Professor
Section of Gastroenterology and Hepatology
Department of Medicine
Baylor College of Medicine

Recent Publications

Moore SR, Guedes MM, Costa TB, Vallance J, Maier EA, Betz KJ, Aihara E, Mahe MM, Lima AA, Oriá RB, Shroyer NF. Glutamine and alanyl-glutamine promote crypt expansion and mTOR signaling in murine enteroids. *Am J Physiol.* 2015;308(10):G831-9.

Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. *Nature.* 2011;470(7332):105-9.


Noah TK, Shroyer NF.. Notch in the intestine: regulation of homeostasis and pathogenesis. *Annu Rev Physiol.* 2013;75:263-88.

Noah TK, Lo YH, Price A, Chen G, King E, Washington MK, Aronow BJ, Shroyer NF.. "SPDEF functions as a colorectal tumor suppressor by inhibiting β -catenin activity. *Gastroenterology.* 2013;144:1012-1023.

Kazanjian A, Noah T, Brown D, Burkart J, Shroyer NF.. "Atonal homolog 1 is required for growth and differentiation effects of notch/ gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells. *Gastroenterology.* 2010;139(3):918-28,

My laboratory is focused on understanding the mechanisms that control intestinal development and homeostasis, and translating this knowledge into novel therapeutic approaches to treat diseases of the intestine such as IBD and colorectal cancer. My laboratory has elucidated roles for epithelial transcription factors such as Atoh1 (Math1), Gfi1, and Spdef in development and differentiation of the intestine. Moreover, my laboratory has translated these findings to human diseases, by showing that Atoh1 and its target Spdef are tumor suppressors that are frequently silenced in colon cancers, and that these genes are essential targets of Notch inhibitory drugs. In addition to these mechanistic studies, we have recently developed novel organ culture methods to direct differentiation of human pluripotent stem cells into intestinal tissue to study intestinal development and disease, and we have used intestinal stem cell-derived organoids in quantitative assays to evaluate intestinal stem cell activity.

Email: noah.shroyer@bcm.edu



ROBERT J. SHULMAN

Functional Gastrointestinal Pain Disorders in Children

Professor

Director, Center for Pediatric Abdominal Pain Research

Director, NIH T32 Training Grant in Pediatric Gastroenterology Research

Children's Nutrition Research Center

Gastroenterology, Hepatology and Nutrition

Department of Pediatrics

Baylor College of Medicine

Recent Publications

Hollister EB, Riehle K, Luna RA, Weidler EM, Rubio-Gonzales M, Mistretta TA, Raza S, Doddapaneni HV, Metcalf GA, Muzny DM, Gibbs RA, Petrosino JF, Shulman RJ, Versalovic J. Structure and function of the healthy pre-adolescent pediatric gut microbiome. *Microbiome*. 2015;26:3:36

Czyzewski DI, Self MM, Williams AE, Weidler EM, Blatz AM, Shulman RJ. Maintenance of Pain in Children with Functional Abdominal Pain. *J Pediatr Gastroenterol Nutr*. 2016;62:3:393-8.

Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. *Aliment Pharmacol Ther*. 2015;42(4):418-27

Symptom Profiles in Patients with Irritable Bowel Syndrome or Functional Abdominal Pain Compared to Healthy Controls.

Varni JW, Shulman RJ, Self MM, Nurko S, Saps M, Saeed SA, Bendo CB, Patel AS, Dark CV, Zacur GM, Pohl JF; Pediatric Quality of Life Inventory Gastrointestinal Symptoms Module Testing Study Consortium. *J Pediatr Gastroenterol Nutr*. 2015 Sep;61(3):323-9.

Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. *Gastroenterology*. 2014;146(6):1500-12.

Up to 20% of school-age children from around the world meet the criteria for recurrent abdominal pain. The primary research interests in our laboratory are these functional gastrointestinal disorders in children with a focus on functional abdominal pain and irritable bowel syndrome. Our goals are to understand the factors contributing to the development of these conditions and to develop effective treatments and management strategies. We are addressing these disorders using a multidisciplinary approach involving collaboration between basic scientists, clinical researchers, psychologists, and other healthcare workers. Studies being carried out including characterizing a) The gastrointestinal microbial contribution to symptoms; b) The contribution of alterations in immune function to the expression of pain; c) The role of low grade gastrointestinal inflammation in producing gastrointestinal symptoms; d) The psychological contributions to pain experience; and e) The genetic contributions to these conditions. Trainees are exposed to various general aspects of clinical research (study design, IRB preparation, data analysis) as well as aspects specific to Pediatric Gastroenterology (e.g., gastroenterologic function testing.)

Email: rs hulman@bcm.edu



BETTY SLAGLE

Hepatitis B Virus Pathogenesis

Associate Professor
Department of Molecular Virology and Microbiology
Associate Director, Center for AIDS Research
Baylor College of Medicine

Recent Publications

Slagle, B.L., Andrisani, O. M., Bouchard, M.J., Lee, C.G.L., Ou, J.-H.J., and Siddiqui, A. Technical standards for hepatitis B virus X protein (HBx) research. *Hepatology* 61:1416-1424, 2015.

Minor, M.M. and Slagle, B.L. Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system. *Viruses* 6:4683-4702, 2014.

Luo, N., Cai, Y., Zhang, J., Tang, W., Slagle, B.L., Wu, X., and He, S. The C-terminal region of the hepatitis B virus X protein is required for its stimulation of HBV replication in primary mouse hepatocytes. *Virus Res.* 165:170-178, 2012.

Hodgson, A. J., Hyser, J. M., Keasler, V.V., Cang, Y., and Slagle, B.L. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. *Virology* 426:73-82, 2012

Kumar M., Jung, S.Y., Hodgson, A.J., Madden, C.R., Qin, J., and Slagle, B.L. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. *J. Virol.* 85:987-995, 2011.

Keasler, V.V., Hodgson, A.J., Madden, C.R., and Slagle, B.L. Hepatitis B virus HBx protein localized to the nucleus restores HBx-deficient replication in HepG2 cells and *in vivo* in hydrodynamically-injected mice. *Virology* 390:122-129, 2009.

Chronic infection with hepatitis B virus (HBV) affects over 400 million people worldwide and is a significant risk factor for severe liver disease, including hepatocellular carcinoma (HCC). The role of HBV in mediating carcinogenesis is complex. The Slagle Laboratory studies HBx, a small HBV-encoded protein that is required for virus replication *in vivo* and is a cofactor for tumorigenesis in transgenic mice. Results from our laboratory and others have shown that the interaction of HBx with cellular damaged DNA binding protein (DDB1) is essential for virus replication. DDB1 is an adaptor protein for the CUL4-DDB1 E3 ligase (CRL4) complex. E3 ligases are multi-unit protein complexes present in all cells, and are responsible for recruiting short-lived proteins for destruction. Many viruses, including HBV, specifically bind to CRL4 in order to alter the spectrum of cellular proteins targeted for degradation. Our goal is to understand how HBx binding to DDB1 alters the normal CRL4 structure and/or function. DDB1 regulates such diverse cellular function as DNA replication, cell cycle, the damaged DNA repair response, and innate immunity. We hypothesize that when HBx interacts with DDB1, it alters some normal DDB1 function that leads to increased virus replication. The identification of such functions may aid in the design of novel antivirals that could halt chronic HBV replication and prevent HCC.

Email: bslagle@bcm.tmc.edu



C. WAYNE SMITH

Obesity and the Inflammatory Process

Professor
Department of Pediatrics
Director of Leukocyte Biology
Children's Nutrition Research Center
Baylor College of Medicine

Recent Publications

Mehta P, Nuoitio-Antar AM and Smith CW. $\gamma\delta$ T cells promote inflammation and insulin resistance during high fat diet-induced obesity in mice. *J Leuk Biol* 97:121-34, 2015

Khan IM, Dai Perrard XY, Perrard JL, Mansoori A, Smith CW, Wu H, Ballantyne CM. Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. *Atherosclerosis*. 233:419-28, 2014

Camell C and Smith CW. Dietary oleic acid increases M2 macrophages in the mesenteric adipose tissue. *PLoS One* 8:e75147, 2013

Wang J, Perrard XD, Perrard JL, Mukherjee A, Rosales C, Chen Y, Smith CW, Pownall HJ, Ballantyne CM, and Wu H. ApoE and the role of very low density lipoproteins in adipose tissue inflammation. *Atherosclerosis*. 223:342-349, 2012

Wang Q, Perrard XD, Perrard JL, Mansoori A, Raya JL, Hoogeveen R, Smith CW, Ballantyne CM and Wu H. Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity. *Atherosclerosis* 219:100-8, 2011

Himes RW, Smith CW. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. *FASEB J*. 24:731-9, 2010

Desai MS, Mariscalco MM, Tawil A, Vallejo JG, Smith CW. Atherogenic diet-induced hepatitis is partially dependent on murine TLR4. *J Leukoc Biol*. 83:1336-1344, 2008

The general purpose of this research is enhanced understanding of how diet alters the balance between the healing and tissue destructive properties of inflammation. We use an animal model of diet-induced obesity in mice, and focus on two general problems associated with obesity: 1) tissue inflammation that may lead to medical complications, and 2) abnormalities in tissue repair, remodeling and wound healing. Specifically, we analyze two types of white blood cells, lymphocytes and macrophages, and their contributions to inflammation of skeletal muscle, liver, pancreas, and fat tissues induced after short-term (days) or long-term (months) feeding a high milk fat diet. We also analyze the influence of a long-term high milk fat diet on the roles of three types of white blood cells (neutrophils, lymphocytes, and macrophages) in tissue remodeling and wound healing. Specific objectives under investigation:

Objective 1. Determine the contributions of $\alpha\beta$ and $\gamma\delta$ T cells to inflammation in skeletal muscle by using a murine model (C57BL/6J, a strain of mice susceptible to diet-induced obesity that develop chronic inflammation similar to that observed in obese humans) of diet-induced obesity; studies will use short- and long-term feeding, techniques for the localization and phenotypic characterization of lymphocytes in skeletal muscle, and techniques for depletion of lymphocyte subsets (earlier work has shown that $\alpha\beta$ and $\gamma\delta$ T lymphocytes are important proinflammatory factors in adipose tissue).

Objective 2. Determine the mechanisms leading to early anti-inflammatory macrophage polarization in mesenteric adipose tissue and the peritoneal cavity of C57BL/6J mice in response to short-term feeding of obesogenic high milk fat diets; determine which macrophage populations exhibit this response and the contributions of dietary oleic acid in modulating the pro-inflammatory effects.

Objective 3. Define how tissue healing (i.e., the positive side of inflammation) is dysregulated in diet-induced obesity, using a model of healing in the cornea of C57BL/6J mice; test the hypothesis that tissue healing depends on a carefully regulated and coordinated inflammatory cascade, and the systemic inflammation of obesity disrupts this cascade with negative effects on normal tissue repair.

Objective 4. Determine whether Matrix Metalloproteinase 12 (MMP12), a tissue remodeling enzyme predominantly expressed in tissue macrophages, influences the development of insulin resistance, tissue inflammation and extracellular matrix remodeling in the context of high-fat diet-induced obesity.

Email: cwsmith@bcm.edu



M. ELIZABETH TESSIER

Microbiome Regulation of Enterohepatic Bile Acid Signaling

Assistant Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition
Texas Children's Hospital
Baylor College of Medicine

Recent Publications

Bile Acid Profiles in Pediatric Patients who Received FMT for Clostridium difficile Infection. Tessier, Mary Elizabeth McConnell¹; Ihekweazu, Faith D; Nagy-Szakal, Dorottya; Crews, Jonathan; Ross, Cana; Oezguen, Numan; Koo, Hoonmo; Wang, Michael; Luna, Ruth Ann; Versalovic, James; Kellermayer, Richard; Savidge, Tor. NASPGHAN Annual Meeting, Washington DC. 2015.

Mary Elizabeth M Tessier, Helen Andersson, Cana Ross, Alex Peniche-Trujillo, Sara Dann, Michael Francis, Joseph Sorg, Sundararajah Thevananther, Margaret E Conner, Tor Savidge. Obeticholic acid (INT-747) confers disease protection against Clostridium difficile infection. Poster Presentation at DDW, Washington D.C. 2015. Winner of AGA/AGA-GRG Fellow Abstract Prize.

Mary Elizabeth M. Tessier, Petri Urvil, Cana Ross, Toni-Ann Mistretta, Shaji K. Chacko, Joseph Sorg, Michael Francis, Alex Peniche-trujillo, Sara M. Dann, Kevin Garey, Tor Savidge. Enterohepatic biomarkers of microbial pathogenesis in Clostridium difficile infection. Poster Presentation at the Liver Meeting, Boston MA. 2014.

Tessier ME, Harpavat S, Shepherd RW, Hiremath GS, Brandt ML, Fisher A, Goss JA. Beyond the Pediatric end-stage liver disease system: Solutions for infants with biliary atresia requiring liver transplant. World J Gastroenterol. 2014 Aug 28;20(32):11062-11068. Review.

Thakkar K, Chen L, Tessier ME, Gilger MA. Outcomes of Children Following Esophagogastroduodenoscopy for Chronic Abdominal Pain. Clin Gastroenterol Hepatol. 2013

Steinke JW, Payne SC, Tessier ME, Borish LO, Han JK, Borish LC. Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis. J Allergy Clin Immunol. 2009 Dec; 124(6): 1352-1354.e7

My laboratory is interested in the enterohepatic circulation and cross-talk between the gut microbiome and hepatic function and health. The farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) signaling pathway is an enterohepatic feedback loop for bile acid homeostasis. Bile acids are reabsorbed in the ileum and activate FXR resulting in FGF19 secretion from intestinal epithelial cells. Portal circulation of FGF19 to hepatocytes inhibits CYP7A1, the rate limiting enzyme in bile acid synthesis from cholesterol. Through the study of *C. difficile* infection, we have examined the role of microbial dysbiosis on bile acid homeostasis via examination of enterohepatic biomarkers. Our studies show that *C. difficile* may exploit the FXR-FGF19 pathway to promote its virulence.

An overarching question is: does microbial dysbiosis alter this feedback loop? I hope to expand our knowledge of the gut microbiome and metabolome in regards to hepatic health, especially in pediatric cholestatic diseases. I plan to continue my studies in *C. difficile* and expand research into dysbiosis and metabolic derangement in hepatic and intestinal disease through collaborations with other Pediatric GI faculty. The ultimate goal is to develop treatments for both adult and pediatric liver and intestinal diseases.

Email: metessie@bcm.edu



Molecular Mechanisms of Liver Regeneration, Non-alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma

Associate Professor
Department of Pediatrics
Gastroenterology, Hepatology and Nutrition

SUNDARARAJAH THEVANANTHER

Recent Publications

Maynard JP, Lee, J-S, Sohn BH, Yu X, Lopez-Terrada D, Finegold MJ, Goss JA & Thevananther S. P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. *Oncotarget*, 2015; 6 (38):41162-79.

Tackett BC, Sun H, Mei Y, Maynard JP, Cheruvu S, Mani A, Hernandez-Garcia A, Vigneswaran N, Karpen SJ, Thevananther S. P2Y2 purinergic receptor activation is essential for efficient hepatocyte proliferation in response to partial hepatectomy. *Am J Physiol Gastrointest Liver Physiol*. 307(11):G1073-87, 2014.

Mei Y, Thevananther S. Endothelial nitric oxide synthase is a key mediator of hepatocyte proliferation in response to partial hepatectomy in mice. *Hepatology* 54(5):1777-89, 2011.

Gonzales E, Julien B, Serrière-Lanneau V, Nicou A, Doignon I, Lagoudakis L, Garcin I, Azoulay D, Duclos-Vallée JC, Castaing D, Samuel D, Hernandez-Garcia A, Awad SS, Combettes L, Thevananther S, Tordjmann T. ATP release after partial hepatectomy regulates liver regeneration in the rat. *Journal of Hepatology* 52:54-62, 2010.

Thevananther S, Sun H, Li D, Arjunan V, Awad SS, Wyllie S, Zimmerman TL, Goss JA and Karpen SJ. Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes. *Hepatology* 39: 393-402, 2004.

The major focus of my laboratory is to understand the cellular and molecular mechanisms responsible for the pathogenesis of non-alcoholic fatty liver disorders (NAFLD) and to gain mechanistic insights into key cellular processes responsible for the temporal progression of hepatic steatosis, steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Previous studies in my laboratory have identified the functional significance of extracellular nucleotides and their cognate P2 purinergic receptor signaling in liver regeneration. Extracellular ATP treatment alone was sufficient to induce cell cycle progression in hepatocytes in vitro, and hepatocyte proliferation in response to 70% partial hepatectomy was attenuated in P2Y2^{-/-} mice.

Transient lipid accumulation within hepatocytes is one of the hallmarks of regenerating livers. Interestingly, P2Y2^{-/-} mice subjected to 70% partial hepatectomy had significant defects in lipid accumulation within hepatocytes. Extracellular ATP treatment alone was sufficient to induce ADFP (lipid droplet associated) protein expression and triglyceride accumulation within hepatocytes in vitro. These early observations were further validated in recent studies with a well-established mouse model of diet-induced obesity. In response to high-fat diet for 22 weeks, C57BL6 mice become obese and develop metabolic syndrome, insulin resistance and NASH. Implicating P2Y2 purinergic signaling in the pathogenesis of NASH, excessive fat accumulation, necro-inflammatory changes and liver injury associated with obesity and metabolic syndrome were significantly attenuated in P2Y2^{-/-} livers.

Major goals: 1) To identify and characterize cell-specific P2Y2 purinergic signaling critical for the induction of hepatic inflammation, dysregulation of lipid homeostasis and hepatocellular injury in response to high-fat diet; 2) To evaluate the feasibility of P2Y2 purinergic receptor antagonism (with infusion of small molecules) to prevent and reverse NASH in mice; 3) To identify key cellular and molecular mechanisms responsible for the induction early neoplastic changes associated with NASH. These studies will specifically address the impact of dysregulation of P2 purinergic signaling in the pathogenesis of HCC.

Email: sundarat@bcm.edu



JAMES VERSALOVIC

Microbiome and Probiotics

Professor
Department of Pathology & Immunology
Vice Chair of Molecular Pathology and Omics
Head, Department of Pathology
Pathologist-In-Chief
Director, Texas Children's
Hospital Microbiome Center
Baylor College of Medicine

Recent Publications

Gao C, Major A, Rendon D, Lugo M, Jackson V, Shi Z, Mori-Akiyama Y, Versalovic J. Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic *Lactobacillus reuteri*. *MBio*. 2015;6(6):e01358-15.

Kellermayer R, Nagy-Szakal D, Harris RA, Luna RA, Pitashny M, Schady D, Mir SA, Lopez ME, Gilger MA, Belmont J, Hollister EB, Versalovic J. Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. *Am J Gastroenterol*. 2015;110(4):604-6.

Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. *Gastroenterology*. 2014;146(6):1449-58.

Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J. Gastrointestinal Microbiome Signatures Of Pediatric Patients With Irritable Bowel Syndrome. *Gastroenterology* 141 (5):1782-91, 2011.

Saulnier DM, Santos F, Roos S, Mistretta TA, Spinler JK, Molenaar D, Teusink B, Versalovic J. Exploring metabolic pathway reconstruction and genome-wide expression profiling in *Lactobacillus reuteri* to define functional probiotic features. *PLoS One*. 29;:e18783, 2011.

Preidis G, Hill C, Guerrant RL, Ramakrishna BS, Tannock GW, Versalovic J. Probiotics, enteric and diarrheal diseases, and global health. *Gastroenterology* 2011;140:8-14.

The Versalovic laboratory seeks to understand the nature of the human metagenome, the microbiome and how microbial communities impact human health and disease. The primary topics of interest in terms of physiology and disease are mucosal immunity, inflammation, nutritional genetics, and the enteric nervous system.

Metagenomics and the Human Microbiome

The laboratory is deeply engaged in the development of new strategies to characterize the composition and dynamics of the human microbiome. Refinement of DNA sequencing and molecular approaches are being deployed to understand the nature of mucosal-associated microbial communities. Currently, we are trying to characterize the intestinal microbiome and the nature of the core microbiome in healthy children. In parallel, we are also studying the changes in the metagenome that may be associated with disorders of mucosal inflammation and recurrent abdominal (visceral) pain. The tools for analysis include multi-omics, enteroids, and mouse models to study the metagenome and human-associated microbial communities.

Neuro-Immunology, Pain, and Inflammation - Mammal and Microbes

Many patients suffer from chronic disorders of inflammation and chronic pain disorders. Our laboratory has chosen to study intestinal inflammation and abdominal pain as opportunities to gain deeper insights into how specific microbes and the microbiome affect the pathophysiology of chronic diseases. With respect to inflammation, mouse colitis models and patients with inflammatory bowel disease (IBD, Crohn's disease) are being studied in order to examine how fluctuations in metagenomes and microbial transcriptomes may affect patterns of mucosal immunity and immune signaling pathways.

Cancer Prevention, Nutrition and the Microbiome

New projects are being developed for exploration of changes in the mammalian microbiome and how the metagenome may help us develop new strategies important for cancer prevention and human nutrition. Already, vitamin biosynthesis and other nutrient pathways have been identified in selected commensal microbes that may have implications for human nutrition.

Bacterial-Host Genetics - Systems Biology - Metabolic Modeling

The laboratory has used a model commensal model organism, *Lactobacillus reuteri*, in order to study how microbes regulate signaling pathways in mammalian cells (mouse and human). Gene expression profiling of commensal bacteria by next generation sequencing has enabled the laboratory to study key genes and pathways in prokaryotes that may provide signals or mediators of microbial: host interactions. Targeted and random mutagenesis strategies are being refined to explore biological pathways in microbial genomes and the metagenome and how these microbial signaling networks may be related to the dynamics of mucosal immunity and neurobiology in mouse models and human patients. New probiotics may be engineered or selected for therapeutic applications.

Email: jamesv@bcm.edu



HUDA Y. ZOGHBI

Molecular Genetic Approaches to Cell Specification and Degeneration

Professor

Department of Molecular and Human Genetics,
Pediatrics, Neurology, and Neuroscience

Director, Jan and Dan Duncan Neurological Research Institute
Texas Children's Hospital
Baylor College of Medicine

Recent Publications

McGraw CM, Samaco RC, Zoghbi HY. Adult neural function requires MeCP2. *Science*. 8;333:186, 2011.

Klish, TJ, Xi Y, Flora A, Wang L, Li W, and Zoghbi HY. The in vivo Atoh1 targetome reveals how a proneural transcription factor regulates neurogenesis. *Proc Natl Acad Sci USA*. 22;108:3288-93, 2011.

Shroyer NF, Helmrath MA, Wang VY, Antalffy B, Henning SJ, and Zoghbi HY. Intestine specific ablation of Mouse atonal homolog 1 (*Math1*) reveals a role in cellular homeostasis. *Gastroenterology*, 132:2478-88. 2007.

Flora A, Klish TJ, Schuster G and Zoghbi HY. Deletion of Atoh1 disrupts sonic hedgehog signaling in the developing cerebellum and prevents medulloblastoma. *Science* 326:1424-7, 2009.

Lim J, Hao T, Shaw C, Patel A, Szabó G, Rual J-F, Fisk CJ, Li N, Smolyar A, Hill D, Barabási A-L, Vidal M, and Zoghbi HY. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. *Cell*, 125:801-14, 2006.

Yang Q, Bermingham N, Finegold, M, and Zoghbi H. Requirement of *Math1* for secretory cell lineage commitment in the mouse intestine. *Science* 294:2155-2158. 2001.

The main focus of my lab is the use of genetic and cell biological and biochemical approaches to explore the pathogenesis of polyglutamine neurodegenerative diseases, the function of *Math1* in neurodevelopment, and how *MECP2* mutations cause postnatal neurodevelopmental disorders have been discovered parallels between neural and intestinal differentiation, which led us to study specification in the developing intestine. In the area of neurodevelopment, we have published work on the molecular pathogenesis of several spinocerebellar ataxias (SCAs) and the role of *Math1* in neuronal fate.

My lab currently has three main projects: 1) Studying mouse models of SCAs, to identify common pathogenic mechanisms in these related diseases. 2) Studying mice with engineered mutations in *MeCP2* (the gene that causes Rett syndrome). 3) The study of the gene *Math1* (*Atoh1*), which governs the development of multiple components of the proprioceptive pathway as well as cerebellar granule cells and hair cells in the inner ear. Somewhat surprisingly, *Math1* also determines the ability of stem cells to differentiate into secretory cells (as opposed to absorptive cells) in the mouse intestine. My group reported that mice lacking *Math 1* have no secretory lineages in the intestinal epithelium (*Science* 2001). Moreover, we started to investigate differentiation events downstream of *Math1* in the intestine, discovering that *Gfi1* functions after *Math1* to specify the different secretory cells (Shroyer et al., 2007). As these mice die at birth, the lab has created a new conditional allele that allows deletion of *Math1* only in the gut in order to study the role of *Math1* in the postnatal intestine and begin to identify downstream targets of this transcription factor.

We also created mice that have *Math1*-flag tagged allele that allowed us to identify *Math1/Atoh1* targets in cerebellar granule precursors. We are using these mice to identify the targets of *Math1* with other cells that require *Math1* for genesis and specification.

Email: hzoghbi@bcm.edu

ELIGIBILITY CRITERIA

ELIGIBILITY CRITERIA FOR CERTIFICATION IN PEDIATRIC GASTROENTEROLOGY (12/09)

Please refer to the American Board of Pediatrics website for complete details.

INFORMATION FOR ALL CERTIFYING EXAMINATIONS

An applicant must satisfactorily complete the standard length of training before the first day of the month in which the examination is administered. An applicant whose contracted training period does not expire before the first day of the month of the examination will not be eligible for that examination, even if all formal training has been completed earlier and the remaining time is used only for leave.

GENERAL CRITERIA FOR CERTIFICATION IN THE PEDIATRIC SUBSPECIALTIES

In addition to the training requirements, which are specific to each of the pediatric subspecialties, the following are required of candidates seeking certification in the pediatric subspecialties of adolescent medicine, cardiology, child abuse pediatrics, critical care medicine, developmental-behavioral pediatrics, emergency medicine, endocrinology, gastroenterology, hematology-oncology, infectious diseases, neonatal-perinatal medicine, nephrology, pulmonology, and rheumatology. Each candidate must be familiar with specific subspecialty training requirements as well as the current rules and regulations in A Guide to Board Certification – Booklet of Information.

A. Certification by the American Board of Pediatrics (ABP)

A candidate for subspecialty certification must have achieved initial certification in general pediatrics and continue to maintain general pediatrics certification in order to take a subspecialty examination. No exceptions to this policy will be granted. The requirements for Maintenance of Certification (MOC) can be found on the ABP website. All candidates are urged to ensure that the requirements for maintenance of certification will be met in sufficient time to allow acceptance to the subspecialty certifying examination. Under certain circumstances, individuals registered for the general pediatrics certifying examination may apply for a pediatric subspecialty certifying examination pending notification of the general pediatrics examination results. Before making application, contact the ABP for information.

B. Licensure

An applicant must hold a valid, unrestricted allopathic and/or osteopathic medical license in at least one jurisdiction in the United States, its territories, or Canada. If licenses are held in more than one jurisdiction, all licenses held by a physician should meet this requirement. Temporary or training licenses are not acceptable. Individuals practicing exclusively abroad, ie., who are not practicing in the United States or Canada, and who do not hold a United States or Canadian license, must provide proof of licensure in the country in which they practice. Applicants for initial certification who intend to practice abroad exclusively must submit a letter stating this fact. In addition, they must submit proof of licensure in the country in which they intend to practice.

C. Verification of Training

Applicants are required to complete training in programs accredited by the Accreditation Council for Graduate Medical Education (ACGME) in the United States or by the Royal College of Physicians and Surgeons of Canada. Those completing training in the United States must have been formally enrolled in the training program and reported annually as a fellow to ACGME and the ABP. An applicant will be asked to list the program(s) where fellowship training occurred as well as the name(s) of the program director(s). The ABP will provide a Verification of Competence Form to the program director(s) for completion. (Note: For new subspecialties, alternatives to the usual training requirements, such as practice experience, will be acceptable as criteria for admission to the examination. Candidates should refer to the specific subspecialty eligibility criteria for details.) The role of the program director in the certification process is to verify training, evaluate clinical competence including professionalism, and provide evidence of the trainee's scholarly activity/research.

The ABP will provide no credit for a year in which clinical competence has been rated as unsatisfactory and will require a repeat year of training. A marginal evaluation in clinical competence indicates the need for remediation of certain portions of clinical training. A trainee may be advanced to a higher level of training under these circumstances as remediation is provided. It is expected that the next year of training will result in a satisfactory evaluation for clinical competence in order for full credit to be provided for the marginal year of training. Two

consecutive marginal evaluations require a repeat year of training.

An applicant must have the verification form(s) on file at the ABP in order to be admitted to the subspecialty examination. If an applicant's training is not verified or if the applicant receives an unsatisfactory evaluation in any of the competencies (with the exception of professionalism alone), the applicant will be required to complete an additional period of subspecialty fellowship training before reapplying. The director of the program where the additional training occurred must complete a separate Verification of Competence Form. If the unsatisfactory evaluation is in professionalism only, the applicant will be required to complete an additional period of fellowship training or, at the program director's recommendation and at the ABP's discretion a period of observation may be required in lieu of additional training. A plan for remediation must be submitted for review and approval by the ABP.

Applicants who wish to appeal evaluations must proceed through institutional due process mechanisms. The ABP is not in a position to reexamine the facts and circumstances of an individual's performance.

An applicant must satisfactorily complete all subspecialty training before the first day of the month in which the examination is administered. An applicant whose contracted training period does not expire before the first day of the month of the examination will not be eligible for that examination, even if all formal training has been completed earlier and the remaining time is used only for leave.

No credit will be given for subspecialty training during the core general pediatric residency or a chief residency.

An applicant seeking certification in another pediatric subspecialty or a non-ABP specialty (e.g., allergy/immunology) on the basis of practice and/or training may not apply the same period of time toward fulfillment of these requirements.

D. Scholarly Activity/Research

The ABP requires scholarly activity during fellowship training. The requirement accommodates a wide variety of academic scholarly activities. **The scholarly activity training requirements (as outlined in Section E (below) apply to all fellows beginning subspecialty training July 1, 2004, and thereafter. Those fellows who began training prior to this date must meet the requirement for meaningful accomplishment in research, which was in place at the time they entered training. Contact the ABP for more information.**

The program director is responsible for notifying all fellows of the scholarly activity requirements necessary for certification upon entry to the subspecialty training program. Furthermore, in the description of the candidate's scholarly activity performance on the Verification of Competence Form, the program director must provide a description of the experiences on which the acceptable evidence of scholarly activity is based.

E. Principles Regarding the Assessment of Scholarly Activity (for those who began training July 1, 2004, and there after)

All fellows must participate in a core curriculum in scholarly activities. This curriculum should provide skills that lead to an in-depth understanding of biostatistics, clinical and laboratory research methodology, study design, preparation of applications for funding and/or approval of clinical or research protocols, critical literature review, principles of evidence based medicine, ethical principles involving clinical research, and the achievement of proficiency in teaching. In addition to participating in a core curriculum in scholarly activities, all fellows will be expected to engage in projects in which they develop hypotheses or in projects of substantive scholarly exploration and analysis that require critical thinking. Areas in which scholarly activity may be pursued include, but are not limited to: basic, clinical, or translational biomedicine; health services; quality improvement; bioethics; education; and public policy.

In addition to biomedical research, examples of acceptable activities might include a critical meta-analysis of the literature, a systematic review of clinical practice, a critical analysis of public policy, or a curriculum development project with an assessment component. Involvement in scholarly activities must result in the generation of a specific written "work product."

Examples of "work products" include, but are not limited to:

- A peer-reviewed publication in which a fellow played a substantial role
- An in-depth manuscript describing a completed project
- A thesis or dissertation written in connection with the pursuit of an advanced degree
- An extramural grant application that has either been accepted or favorably reviewed
- A progress report for projects of exceptional complexity, such as a multi-year clinical trial

Review of scholarly activity and the written work product will occur at the local level with each Fellow having a Scholarship Oversight Committee responsible for overseeing and assessing the progress of each Fellow and verifying to the ABP that the requirement has been met. The Scholarship Oversight Committee should consist of three or more individuals, at least one of whom is based outside the subspecialty discipline; the Fellowship program director may serve as a trainee's mentor and participate in the activities of the oversight committee, but should not be a standing (i.e., voting) member.

Upon completion of training, the ABP will require:

- Verification from the training program director that the clinical and scholarly skills requirements have been met
- A comprehensive document (i.e., personal statement), written by the Fellow, describing the scholarly activity that includes a description of his/her role in each aspect of the activity and how the scholarly activity relates to the trainee's own career development plan. The Fellow's personal statement, ie, a comprehensive document written by the Fellow, is integral to the requirement for scholarly activity. This document should be several pages in length and comment on the Fellow's intended career path upon entering Fellowship and reasons for choosing a specific area of scholarly activity. It should describe the scholarly activity and the Fellow's role in each aspect of the activity, as well as any preparation beyond the core Fellowship curriculum needed to ensure successful completion of the project. The personal statement should describe how the scholarly activity furthers the Fellow's career development plan, and should reflect upon the educational value of the pursuit of the project;
- The actual "work product" of the scholarly activity as described above;
- Signature of the Fellow, program director, and members of the Scholarship Oversight Committee on both the personal statement and work product of the Fellow as described above.

Details of the scholarly activity requirement have been published by the ABP in a document entitled [Training Requirements for Subspecialty Certification](#) (January 2004), which is downloadable directly from the ABP's Web site.

Fellows completing training in RCPSC accredited programs must meet the ABP's requirements for scholarly activity under the mentorship of a Scholarship Oversight Committee, as defined by the ABP above. Scholarly Activity began in the third year of training will not meet the requirement.

F. Miscellaneous Policies/Issues Related to Certification and Training

Transfer of Fellowship Training

While not encouraged for continuity purposes, if a fellow must transfer, the program directors of the current program and the proposed program must communicate to ensure that the fellow who transfers will meet all requirements if he or she desires to apply for a certifying examination in the subspecialty. A Fellow Transfer Information (FT11) form should be completed by the current program director and submitted to the ABP with a copy to the proposed new program. Fellow evaluations should be submitted to the proposed program as well. Months of credit for clinical experience and scholarly activity/research completed must be clearly communicated to the fellow, the new program director, and the ABP. The ABP must be informed of the plan to ensure continued appropriate mentoring for scholarly activity upon transfer, including the role of the Scholarship Oversight Committee. The ABP will send summary evaluations to a new training program if a fellow transfers.

Interruption of Training

Fellows who interrupt fellowship training for greater than 12 continuous months and who wish to re-enter training fellowship training must petition the ABP to determine whether credit may be awarded for prior training. The request for credit must be submitted by the candidate or the fellowship director before the fellow re-enters fellowship training.

Program Requirements for Residency Education in the Subspecialties of Pediatrics

Program Requirements for Residency Education in the subspecialties of pediatrics are approved by the Accreditation Council for Graduate Medical Education (ACGME) or by the Royal College of Physicians and Surgeons of Canada (RCPSC). Program Requirements and a listing of accredited programs may be found on the ACGME website: www.acgme.org, or the RCPSC website: rcpsc.medical.org.

Training Leading to Dual Pediatric Subspecialty Certification

Sequential Dual Training:

If an individual has completed 3 years of training in one subspecialty and the program director has verified both clinical competence and satisfactory completion of scholarly activity, he or she can become eligible to take an examination in a second subspecialty after 2 years of additional training, of which at least 1 year must be broad-based clinical training. The requirement for scholarly activity in the second subspecialty is waived. Individuals approved for subspecialty fast-tracking in the first subspecialty are also eligible for this pathway. This dual training option does not require preapproval by the ABP.

Integrated Dual Training:

An individual and his or her program director(s) may petition the Credentials Committees of two pediatric subspecialties with a proposal for a 4- or 5- year integrated training program that would meet the eligibility requirements for certification in both subspecialties. Petitions for this option must be approved before subspecialty training begins or early in the first year of subspecialty training. Guidelines for dual subspecialty training may be obtained from the ABP or can be found on the ABP website.

Training Leading to Eligibility for Combined (Internal Medicine-Pediatrics) Subspecialty Certification

An individual who has completed internal medicine-pediatrics training should contact the American Board of Internal Medicine and the American Board of Pediatrics regarding opportunities for combined training (i.e., training in both the adult and pediatric subspecialties). Combined training petitions must be submitted prospectively either before training begins or in the first 3 to 6 months of fellowship training and must be approved by both boards. All training in the internal medicine and pediatric subspecialty must be completed in order for an applicant to take a pediatric subspecialty certifying examination. Guidelines for combined training may be obtained from the ABP or can be found on the ABP website.

Subspecialty "Fast-Tracking"

A subspecialty fellow who is believed to have demonstrated accomplishment in research, either before or during residency, may have a part of the training requirement waived. Evidence of such accomplishment might include a PhD in a discipline relevant to the subspecialty or career path of the fellow, or sustained research achievement relevant to the subspecialty or career path of the fellow. The subspecialty program director may petition the Subboard to waive the requirement for scholarly activity, and to reduce the length of subspecialty training by as much as 1 year. This petition must be made either before the beginning of training or during the first year of training.

A candidate for this pathway must have satisfactorily completed 3 core years of pediatrics or approved combined pediatrics and other specialty training in an accredited program in the US or Canada. This pathway is also available to candidates who have satisfactorily completed at least 3 years of non-accredited general pediatrics training (eg, overseas) and qualified for a waiver of 1 year of general pediatrics training through the Policy Regarding Individuals with Non-Accredited Training. An individual who enters subspecialty training via the Accelerated Research Pathway would not be eligible for subspecialty fast-tracking.

A subspecialty fellow who receives a waiver by the Subboard must complete at least 2 years of training in the subspecialty with at least 1 year of broad-based clinical training. In order for an individual to be eligible for subspecialty certification, all requirements for general pediatrics certification must be fulfilled.

Time-limited Eligibility for Initial Certification Examinations

Beginning with the examinations administered in 2014, the American Board of Pediatrics will require that applicants have completed the training required for initial certification in the pediatric subspecialties within the previous 7 years (e.g., 2007 or later for examinations administered in 2014). If the required training was not successfully completed within the previous 7 years, the applicant must complete an additional period of supervised practice in order to apply for certification. The subspecialty examinations are offered every other year. Therefore, please note that the pediatric subspecialty examination may not be offered in the year the acceptance expires. The full policy can be found on the ABP website.

Closure of Practice Pathway for Subspecialty Certification

The ABP has established a policy for a closure date for the practice pathway for all subspecialties in which a certificate is offered. The certifying examinations for 2010 were the last examinations for which an individual could apply for certification using practice experience accrued by the deadline stated in the original eligibility criteria when the subspecialty was established. A candidate qualifying for the child abuse pediatrics examination via the practice pathway had until 2013 to apply for certification.

It should be noted that these criteria and conditions are subject to change without notice. All applicants should be familiar with the current Booklet of Information. Applicants are advised to contact the ABP to ascertain whether the information they have is current.

9/15

ELIGIBILITY CRITERIA FOR CERTIFICATION IN PEDIATRIC GASTROENTEROLOGY (11/15)

The American Board of Pediatrics (ABP) has established a procedure for certification in pediatric gastroenterology. In addition to the specific admission requirements listed below, General Eligibility Criteria for all ABP Subspecialties [1] must be fulfilled to be eligible for certification.

ADMISSION REQUIREMENTS

Three years of full-time, broad based fellowship training in pediatric gastroenterology are required to be completed in a program accredited for training in pediatric gastroenterology by the Accreditation Council for Graduate Medical Education in the United States or the Royal College of Physicians and Surgeons of Canada.

No continuous absence of more than 1 year will be permitted. Combined absences/leaves in excess of 3 months during the 3 years of training, whether for vacation, parental leave, illness, and so forth, must be made up. If the program director believes that combined absences/leaves that exceed 3 months are justified, a letter of explanation should be sent by the director for review by the Credentials Committee. Part-time training may be completed over no more than 6 years.

The following must be accomplished in order to become certified in the subspecialty:

- A Verification of Competence Form must be completed by the program director(s) verifying satisfactory completion of the required training, evaluating clinical competence including professionalism, and providing evidence of scholarly activity/research.
- The fellow must meet the criteria stated in the "Principles Regarding the Assessment of Scholarly Activity."
- The fellow must pass the subspecialty certifying examination.

It should be noted that these criteria and conditions are subject to change without notice. All applicants are advised to contact the ABP to ascertain whether the information they have is current.



